

Funding Opportunities Monthly Edition July 2025 Due Dates

<u>Introduction</u>

This funding opportunity packet contains information on funding opportunities with deadlines in July 2025.

The opportunities are organized in the following order:

- 1. National Institutes of Health (NIH)
- 2. National Science Foundation (NSF)
- 3. Other Federal
- 4. Non Federal

The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 below for assistance or questions.

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
11/////	NCI Clinical and Translational Expl Clinical Trial Optional)	loratory/Developmental Studies (R21	National Cancer Institute/NIH	PAR- 25-139 12	Jun-2025	275,000 USD
	Contact Name	Morgan O'Hayre, Ph.D.				
	Contact Telephone	240-276-7482				
	Contact Email	ohayrem@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Jun-2025 , 01-Jul-2025				
	Synopsis	This Funding Opportunity Announcem studies, directly related to advanceme management, or reduction of cancer of following: new molecular agents or bid treatment-related toxicity; cancer screapproaches; predictive and prognostic vitro tumor models (including geneticalines); and strategies to address theraphew treatment strategies may involve on established mechanisms of action. health disparities are encouraged to expensive to therapeutic interventions diagnosis of human disease are supported (such as studies of cancer-related patherisk assessment studies, epidemiological not responsive to this FOA and will not responsive for this FOA). The R21 mechanism support for the early and couled to breakthroughs in particular are applications that could have a major in	nts in cancer treatment, diagnoralisparities. This includes (but is rologics for cancer treatment; makening or diagnostic tools, such a biomarkers for patient selectionally engineered mouse models, poeutic outcome disparities amore repurposed agents or novel cor Comparative correlative studies explore mechanisms underlying to a Comparative oncology studies red as well. This FOA does not shaways, molecular mechanisms, or all studies, or studies of behavioral studies, or studies of behavioral studies, or studies of behavioral studies, or to the development of notices.	isis, prevention, companion limited to) developmenagement strategies for as imaging techniques; in or stratification; clinic patient-derived xenograme underserved popular mbinations of intervents in cancer patients with their differential responsion in the series in dogs investigating series in the series in	rative oncology, soment and testing of cancer-related cancer preventive cally relevant in violatt models, organitions. In additionations (including radials, gender, races (efficacy and strategies for treat ocuses on basic castasis), late-stage e applications will on of studies that lopmental research volve considerables.	ymptom of the symptoms or e agents or ivo or in oids, and cell to novel agents, diation), based ial/ethnic, or toxicity) and tment and encer biology clinical trials, l be deemed are not ch projects by le risk but may
1 / 1 X / h		on of Biomarker Assays Developed Grants (R01 Clinical Trial Not Allowed)	National Cancer Institute/NIH	I/DHHS PAR- 24-304 11	Jul-2025	450,000 USD

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	-------------------

Contact Name Sumana Dey, Ph.D.

Contact Telephone 240-276-5748

Contact Email <u>sumana.dey@nih.gov</u>

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 11-Jul-2025, 15-Oct-2025, 13-Feb-2026, 10-Jul-2026, 14-Oct-2026

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) encourages revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose projects that are expected to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of applications submitted in response to this NOFO should be on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer prevention and control. Applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed in response to this NOFO encourage multidisciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This NOFO is not intended to support early-stage development of technology or the conduct of

clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials

113232 Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)

National Cancer Institute/NIH/DHHS

PAR-22-242 07-May-2025 Not Specified

Contact Name Rao Divi, Ph.D.

Contact Telephone 240-276-6913

Contact Email divir@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 07-May-2025, 05-Jun-2025, 05-Jul-2025, 07-Sep-2025

as investigational assays/tools/devices.

The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) develop, integrate,

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	optimize, validate, translate or accelera and address specific research or clinical enhancing our understanding of health design-directed, developmental, discove applying an integrative approach to incr science.	problem in basic, translational, an and disease, and/or c) improve pro ery-driven, or hypothesis-driven re	nd/or clinical science actice of medicine. esearch, and this FC	e and practice, b) Applications may DA is appropriate f	capable of propose or small teams
113233 Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DH	IHS PAR- 07-I	May-2025	Not Specified
Contact Name	Rao Divi, Ph.D.				
Contact Telephone	240-276-6913				
Contact Email	divir@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 05-Jul-202	5 , 07-Sep-2025			
Synopsis	The purpose of this funding opportunity that: 1) apply a multidisciplinary bioeng validate, translate or otherwise accelerator clinical problem in basic, translational developmental, discovery-driven, or hypapproach to increase our understanding support clinical trials that test functional conventional clinical trials that lack translany area of research are not sought by a commercial production.	ineering approach to the solution ate the adoption of promising tool I, or clinical science and practice. A pothesis-driven research and is apply of and solve problems in biologic lity or validate performance in the slation as the primary motivation.	of a biomedical pros, methods, and tec An application may propriate for small al, clinical, or trans e chosen setting. Th Applications that p	oblem; and 2) interchniques for a spe propose design-d teams applying ar lational science. his FOA is not inter propose phase III o	grate, optimiz cific research irected, n integrative This FOA will nded to suppo linical trials in
Notice of Special Interest (NOSI): 113746 Study Designs for Liquid Biopsy A. Cancers	Utilization of Cohorts and Prospective ssay Validation for Early Detection of	National Cancer Institute/NIH/DH	NOT- IHS CA-23- 07-I 004	May-2025	Not Specified
Contact Name	Matthew Young, Ph.D.				



Contact Telephone 240-276-5846

SPIN ID	N ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Sponsor Website	matthew.young@nih.gov Link to program URL				
	_	07-May-2025 , 05-Jun-2025 , 12-Jun-2025	i , 01-Jul-2025			
	, ,	The purpose of this Notice of Special Inte biomarker technology developers with as and biorepository researchers. Proposals and validation utilizing statistically power populations with a sound study design ar	says for early cancer detection, that facilitate early cancer biom ed retrospective cohorts and/or	and population-bas arker assay develo	sed researchers, inc pment, verification	cluding cohort , qualification,
1/3/41 -	ICCIH Natural Product Mid Phase R01 Clinical Trial Required)		National Center for Complement and Integrative Health/NIH/DHH	·) \ -	Jun-2025	1,750,000 USD
	0	Callad Children AA D. AADU				

Contact Name Sekai Chideya, M.D., MPH

Contact Telephone 301-827-1916

Contact Email sekai.chideya@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 23-Jun-2025, 17-Jul-2025, 23-Feb-2026, 17-Mar-2026, 20-Oct-2026, 13-Nov-2026

This Funding Opportunity Announcement (FOA) invites cooperative agreement applications for investigator-initiated midphase clinical trials of natural products. All applications submitted under this FOA must be supported by sufficient preliminary data of bioavailability and documentation that the natural product produces a replicable and measurable impact on a biological signature (i.e., measure of the mechanism of action). Only in cases when it is not possible/practical to measure a biological signature in the patient population of interest or when there is a fundamental understanding of the product's mechanism of action will this preliminary data requirement be waived. Applications submitted to this FOA should propose a Synopsis mid-phase clinical trial to do the following: determine the optimal dose or formulation of a given natural product for use in a future multi-site clinical trial; or determine which patient phenotypes will be responders versus non-responders to the

natural product to inform inclusion/exclusion criteria of a future efficacy study. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This FOA will not support single-site or multi-site efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research

contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

	o	• •			
SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
123147 NCCIH Multi-Site Feasibility Clinic (R01 Clinical Trial Required)	al Trials of Mind and Body Interventions Na	ational Center for Complement	/()=1	un-2025	Not Specified
Contact Name	Pete Murray, Ph.D.				
Contact Telephone	301-496-4054				
Contact Email	peter.murray@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	20-Jun-2025 , 15-Jul-2025 , 20-Oct-2025 , 1 , 17-Nov-2026	18-Nov-2025 , 20-Feb-2026 , 17	7-Mar-2026 , 22-Jun-	2026 , 14-Jul-202	6 , 20-Oct-2026
Synopsis	This notice of funding opportunity (NOFO) integrative health approaches with physical interventions) in NCCIH-designated areas opropose a multisite feasibility clinical trial and conduct of a subsequent clinical efficatrial within NCCIH's mission. NCCIH expects oding demonstrate that the proposed (I powered, full-scale clinical trial. Under this including, but not limited to the following: demonstrating feasibility of recruitment, a adherence to the intervention, as well as rethe feasibility of protocolized multimodal i preparation for a future fully powered, multipreparation for a future fully powered, multipreparation for a future fully powered, multipreparation for a future fully powered multisite clinical submitting to this NOFO, applicants are enthe science area of the planned application be assessed as part of the scientific and teconsidered incomplete and will be withdrawand view the available PEDP guidance mat	al and/or psychological therape of high research priority. Applications that will provide new informating or effectiveness study, prages that applications to this NOFORO1) research is scientifically new assessing whether the intervelocation of participants through the interventions, and/or demonstrative efficacy or effectiveness minary data from previous single ould be used to fill gaps in sciential that has the potential to accouraged to contact the approach. This NOFO requires a Plan for chnical peer review evaluation are strongly en	eutic inputs (often catations submitted un con that is scientifical matic trial, or dissent O will describe the precessary to design of distribution can be delivered articipants across site thout the study acropating feasibility of distribution trial. The need for reflection to the site of the site feasibility or another than the significant in priate NCCIH Scientific Reports of the site	alled mind and boarder this NOFO are ally necessary for the innation and implicanced future climater plan the subsequent in scientific knowed with fidelity actes; demonstrating a lata collection acrultisite feasibility acceptability trial (all be necessary to impact on public here perspectives (PE ail to include a PE	e expected to the planning ementation nical trial and in uent fully yledge, cross sites; ag participant and assessing coss sites in y trials is s) or the develop a ealth. Prior to tact person for DP), which will EDP will be



123153 Investigator Initiated Clinical Trials of Complementary and Integrative

National Center for Complementary

PAR-

20-Jun-2025

Not

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Interventions Delivered Remotely Required)	or via mHealth (R01 Clinical Trial	and Integrative Health/NIH/DHH	S 25-268		Specified
	Contact Name	Beda Jean-Francois, Ph.D.				
	Contact Telephone	202-313-2144				
	Contact Email	beda.jean-francois@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	20-Jun-2025 , 14-Jul-2025 , 20-Oct-202 , 17-Nov-2026	5 , 17-Nov-2025 , 20-Feb-2026 , 17	7-Mar-2026 , 22-Jun	-2026 , 13-Jul-202	6 , 20-Oct-2026
	Synopsis	This Notice of Funding Opportunity (NC conducted clinical trials to assess the expectation of the NCCIH- designated areas of high resear remotely delivered and conducted fully participants and may utilize mHealth to approach and provide preliminary data intervention has promise of clinical ber Scientific/Research contact for the area to this NOFO. This NOFO requires a Plascientific and technical peer review evalue withdrawn. Applicants are strongly equidance material.	fficacy or effectiveness of compler och priority. Applications submitted powered clinical trial with no inspects or technologies. Applicants must on the feasibility and safety of the nefit. Applicants are encouraged a of science for which they are planan for Enhancing Diverse Perspect aluation. Applications that fail to in	mentary and integral dunder this NOFO a person contact betweet provide justificate approach, along we to contact the approach ives (PEDP), which we clude a PEDP will be	tive health intervented to proveen research staffition for the remotivith evidence that opriate NCCIH application prior to will be assessed as see considered inco	entions in oppose a fand study ely delivered the consumpting part of the mplete and wil
123152	Feasibility Clinical Trials of Mind a Priority Research Topics (R34 Clinical Trials of Mind a	nd Body Interventions for NCCIH High ical Trial Required)	National Center for Complement and Integrative Health/NIH/DHH	· /()_	Jun-2025	450,000 USD
	Contact Name	Jennifer N. Baumgartner, Ph.D.				
	Contact Telephone	301-402-4084				
	Contact Email	jennifer.baumgartner@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	20-Jun-2025 , 14-Jul-2025 , 20-Oct-202	5 , 17-Nov-2025 , 20-Feb-2026 , 17	'-Mar-2026 , 22-Jun	-2026 , 13-Jul-202	6 , 20-Oct-2026



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding
5. IIV 12		Sponsor Hume	Sponsor Humber	Deadine Date	Amount

17-Nov-2026

The goal of this notice of funding opportunity (NOFO) is to support feasibility trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions that have been identified by NCCIH as high-priority research topics. This funding opportunity is intended to support feasibility clinical trials that provide new information that are scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIH's mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent competitive full-scale clinical trial. Under this R34, the data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive fullscale clinical trial, including, but not limited to the following: examining feasibility and acceptability of interventions lacking Synopsis published data; tailoring or adapting the content or structure of an intervention to a specific population, modality, or setting; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention, and data collection procedures; refining and assessing the feasibility of protocolized multi-component interventions; or examining acceptability and adherence of control conditions. The subsequent full-scale clinical trial should have the potential to make a significant impact on public health. Prior to submitting to this NOFO, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP

Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated 123155 Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required)

National Center for Complementary and Integrative Health/NIH/DHHS

20-Jun-2025

500.000 USD

Contact Name Elizabeth Ginexi, Ph.D.

Contact Telephone 301-827-0160

Contact Email elizabeth.ginexi@nih.gov

guidance material.

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 20-Jun-2025, 14-Jul-2025, 20-Feb-2026, 17-Mar-2026, 22-Jun-2026, 14-Jul-2026

This notice of funding opportunity (NOFO), utilizing the U24 grant funding mechanism, encourages applications for a collaborating data coordinating center (DCC) application that accompanies an investigator-initiated multi-site clinical trial

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	-------------------

(Phase III and beyond) application submitted under companion PAR-24-275. The DCC application must be specific to the companion clinical coordinating center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this NOFO applies must be relevant to the research mission of NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult the NCCIH website (https://www.nccih.nih.gov). Applicants are encouraged to contact the appropriate Scientific/Research Contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

123858

Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Required)

National Center for Complementary and Integrative Health/NIH/DHHS

PAR-23-Jun-2025 24-313

Not Specified

Contact Name Wendy Weber, N.D., Ph.D, M.P.H.

Contact Telephone 301-402-1272

Contact Email weberwi@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 23-Jun-2025, 15-Jul-2025, 20-Feb-2026, 17-Mar-2026, 22-Jun-2026, 14-Jul-2026

This Notice of Funding Opportunity (NOFO), utilizing the U24 grant funding mechanism, encourages applications for a collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi-site clinical trial (Phase III and beyond) application submitted under PAR-24-312. The DCC application must be specific to the collaborating Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this NOFO applies must be relevant to the research mission of NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult the NCCIH website: (https://www.nccih.nih.gov). Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).

Synopsis

SPIN ID Program Title		Sponsor Name	Sponsor Numb	per Deadline Date	Funding Amount
Clinical Coordinating Center for N 128271 Clinical Trials of Mind and Body In Clinical Trial Required)	CCIH Multi-Site Investigator-Initiated aterventions (Collaborative UG3/UH3	National Center for Complement and Integrative Health/NIH/DHH	•	21-May-2025 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Elizabeth Ginexi, Ph.D.				
Contact Telephone	301-827-0160				
Contact Email	elizabeth.ginexi@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	21-May-2025 [Optional][LOI/Pre-App], Mar-2026 , 23-May-2026 [Optional][LO			l][LOI/Pre-App], 20-Fe	b-2026 , 17-
Synopsis	This notice of funding opportunity (NO) efficacy, effectiveness, or pragmatic triphysical and/or psychological therapeu interventions that include physical, psy priority. Clinical coordinating centers (C (Phase III and beyond). The objective of and operational plan for the clinical tripparticipant recruitment and retentions CCC applications submitted under this funding mechanism. In addition, an acc 24-087 and proposing a data analysis and a corresponding DCC application minformation about the mission, strategi NCCIH website (https://nccih.nih.gov/a Contact for the area of science for which Notice of Funding Opportunity (NOFO)	als) to study the effects of completic inputs (often called mind and be chological, and/or nutritional approach should develop and implement a CCC application is to present that CCC applications are expected that trategies, performance milestone. NOFO will utilize a two-phase, milestone and data management plan for the eed to be submitted simultaneous c vision, and research priorities of about/plans). Applicants are encount they are planning to develop and	mentary and in- pody intervention roaches in NCCI nt the proposed re scientific ration to describe plans s, scientific condestone-driven consider ter (DCC) applical clinical project, ly for consideral NCCIH, applical raged to contact application price	tegrative health appropriately and/or multicom H-designated areas of fully powered multisionale and a comprehes for project managem duct, and dissemination (U24), submitten is required. Both a CC tion by NCCIH. For adonts are encouraged to the appropriate Scient to submitting to this	paches with ponent high research te clinical trial nsive scientificment, on of results. (UG3/UH3) d under PAR-IC application ditional consult the entific/Research
113395 NIAID Research Opportunities for Promote Workforce Diversity (RO:	New and "At-Risk" Investigators to 1 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR- 22-241	07-May-2025	Not Specified
Contact Name	Diane Adger-Johnson, MPH				



Contact Telephone

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	AlTrainingHelpDesk@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2025 , 05-Jun-2025 , 05-Jul-202	25 , 07-Sep-2025			
	Synopsis	The purpose of this funding opportunity mission. This FOA seeks to support eith successfully for substantial, independent support as a PD/PI on a substantial independent award in the current fiscal year, will have backgrounds, including those from grounds.	er (a) a New Investigator (NI), an interesting to the funding from NIH, or (b) are an bependent research award and unlewe no substantial research grant fur	ndividual who has n At-Risk' investigato ess successful in sec anding in the followi	not previously com r, an individual wh uring a substantia	npeted no had prior I research gra
1//354	Exploratory Clinical Trial Grants in Diseases (R61 Clinical Trial Require	Arthritis and Musculoskeletal and Skin ed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	DAK-	Jul-2025	600,000 USD
	Contact Name	Yan Wang, M.D., Ph.D.				
	Contact Telephone	301-594-5032				
	Contact Email	wangy1@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	02-Jul-2025 , 04-Nov-2025 , 04-Mar-20	26 , 02-Jul-2026 , 02-Nov-2026			
	Synopsis	This Notice of Funding Opportunity (NC frame. A broad range of types of explor questions related to the mission and go surgical, dietary, behavioral or rehability	ratory studies may be submitted to pals of the NIAMS and may evaluat	this NOFO. The tria	als must address r	esearch
1 / / / 61	Clinical Observational (CO) Studie Skin Diseases (R01 Clinical Trial No	s in Musculoskeletal, Rheumatic, and ot Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-	Jul-2025	475,000 USD
	Contact Name	Yan Wang, M.D., Ph.D.				



Contact Telephone 301-594-5032

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	1				
	wangy1@mail.nih.gov				
Sponsor Website					
_	Link to program URL				
Deadline Dates (ALL) 02-Jul-2025 , 04-Nov-2025 , 04-Mar-20				
Synopsis	The purpose of this Notice of Funding (pursue clinical observational (CO) studing rheumatic, or skin diseases or condition clinical study design by providing essent comorbid conditions; availability of potential can facilitate efforts to develop and/or clinical study. A future clinical study may encouraged to propose studies that ad determining the appropriate primary of patients are most likely to respond to a	es to obtain data necessary for dens. Research data from observation tial information about disease symptomical research participants; and ovalidate objective biomarkers or say include a clinical trial or an observations of secondary outcome measures on intervention. Only observational	esigning clinical studers and studies supporter and studies supporter and sutcomes that are in subjective outcome ervational study. Appetions in the design or identifying the stages studies will be sup	ies for musculosked by this NOFO call timing of disease mportant to patien measures for use plicants to this NO of a clinical project ges of disease duri	eletal, an enhance progression; ats. They also in a future FO are c, such as ng which
126137 NIAMS Clinical Trial Implementate Clinical Trial Required)	ion Cooperative Agreement (UG3/UH3	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-	Jul-2025	Not Specified
Contact Name					
Contact Telephone					
Contact Emai	NIAMSclinicaltrials@mail.nih.gov				
Sponsor Website					
Program URI	Link to program URL				
Deadline Dates (ALL) 02-Jul-2025 , 04-Nov-2025 , 04-Mar-20	26 , 02-Jul-2026 , 02-Nov-2026 , 0	4-Mar-2027		
Synopsis	This Notice of Funding Opportunity And implementation of investigator-initiate completed all necessary preparation (es may apply for a NIAMS UG3/UH3. The to start the trial, (e.g., establishing the Transition to the UH3 phase to begin the investigator and approved by NIAMS.	d, single or multi-site, intervention .g., the trial design, protocol syno UG3 phase is designed to allow the single IRB (sIRB), contracts and refricted is dependent upon complested.	nal clinical trials (all psis, data analysis pl e investigators to pr liance agreements w tion of the UG3 mile	phases). Investigation, etc.) through of the final aspoint in the final	tors who have other means pects needed staff, etc.).

SPIN ID Program Title			Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	and prioritized for tra- clinical impact within	·	hase. NIAMS expects trials to b n of NIAMS.	e hypothesis-driven	and have the pot	ential for high
126760 Advancement and Innovation and Predictors (R21 Clinical 1			ational Institute of Child Health uman Development/NIH/DHHS	Ih-	Jun-2025	275,000 USD
Contact Telep	Iame Virginia Salo hone 301-402-3682 Email <u>virginia.salo@nih.gov</u>	:				
Sponsor We Program	bsite URL Link to program URL					
Deadline Dates	, 16-Nov-2026 , 16-Fel	b-2027 , 16-Mar-202	16-Nov-2025 , 16-Feb-2026 , 16 7 , 16-Jun-2027 , 16-Jul-2027			
Syn	conceptualization of copsis development of novel focused, culturally and	qualities of the envir I measures of childre d linguistically respo impairment, and pre	ortunity (NOFO) is to encourage conment that can support langu en's language development. The nsive, and generalizable tools t dictors thereof. This Notice of	age development in e overall goal is to b o further our unders	children and that uild the number o standing of childre	focuses on the f strengths- en's language
126762 Advancement and Innovation and Predictors (R01 Clinical T			ational Institute of Child Health uman Development/NIH/DHHS	115-	Jun-2025	Not Specified
Contact Telep	lame Virginia Salo hone 301-402-3682					
Contact I Sponsor We	Email <u>virginia.salo@nih.gov</u> bsite					
Program Deadline Dates			05-Nov-2025 , 05-Feb-2026 , 05 7 , 05-Jun-2027 , 05-Jul-2027	5-Mar-2026 , 05-Jun	-2026 , 05-Jul-202	6 , 05-Oct-2026
Syn			ortunity (NOFO) is to encouragonment that can support langu			



SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber Deadline Date	Funding Amount
		development of novel measures of chil focused, culturally and linguistically residevelopment and/or impairment, and will be assessed as part of the scientific be considered incomplete and will be volverse Perspectives (PEDP).	sponsive, and generalizable tools to predictors thereof. This NOFO requ c and technical peer review evalua	o further our ur lires a Commul tion. Applicatio	nderstanding of childre nity Engagement (CE) F ons that fail to include	n's language Plan, which a CE Plan will
1 /X / 4 5	Continuation or Revision of NIDCF mplementation Cooperative Agre	R Clinical Trial Planning and eement (UH3 Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR- 25-062	08-May-2025	Not Specified
	Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis	dena.fischer@nih.gov	Mar-2027, 06-May-2027, 07-Jul-2 DFO) will accept applications for co I Institute of Dental and Craniofacia lication will be supported when the up is well justified to assess longer stification for modifying the scope cientific/Research contact assigned	027, 08-Sep-20 mpeting renew of Research (NI ere is need for a term outcome of the ongoing I to the ongoin	027, 08-Nov-2027, 06 val or competitive revidence of an object of an o	-Jan-2028 sion of ongoing ongoing clinical plete the trial as will be ongly
129390 <u>R</u>	FA-DK-26-006 NIDDK Catalyst	Award (DP1 Clinical Trial Not Allowed)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	RFA- DK-26- 006	18-Jun-2025 [Optional][LOI/Pre- App]	2,500,000 USD
	Contact Name Contact Telephone	Carol Haft, Ph.D. 301-594-7689				



Contact Email haftc@mail.nih.gov

Sponsor Website

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program URL				
	Deadline Dates (ALL)	18-Jun-2025 [Optional][LOI/Pre-App], 1	.8-Jul-2025			
	Synopsis	The NIDDK Catalyst Award is designed to complement NIDDK's traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and transformational studies in topic areas of interest to NIDDK's Division of Diabetes, Endocrinology and Metabolic Diseases, and to NIDDK's Division of Digestive Diseases and Nutrition. Applications should be focused on major scientific challenges and have the potential to produce an unusually high impact or diseases and conditions that are central to the mission of these two divisions within NIDDK. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigator's research program or elsewhere.				
129740 Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)		National Institute of Diabetes an Digestive and Kidney Diseases/NIH/DHHS	PΔR-	May-2025	Not Specified	
	Contact Name	Mary Evans, Ph.D.				
	Contact Telephone	301-594-4578				
	Contact Email	evansmary@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-May-2025 , 10-Jun-2025 , 09-Jul-2025 , 07-Aug-2025 , 09-Sep-2025 , 09-Oct-2025 , 07-Nov-2025 , 09-Dec-2025 , 09-Jan-				
	Synopsis	This Funding Opportunity Announcemeresearch to evaluate a new policy or practivity, sedentary behavior, and/or sleintended to support research where opexpedited review and funding. All appliance application due date; however, administration	ogram that is likely to influence of ep) and/or weight outcomes in an portunities for empirical study are cations submitted to this FOA mu- ommon and scientifically-compell delay. For these reasons, applicat I that eligible applications selected	pesity related behaven n effort to prevent on e, by their very natur st demonstrate that ing research opport ions submitted to the d for funding will be	iors (e.g., dietary in reduce obesity. If re, only available to the evaluation of unity that will only is time-sensitive fawarded within 4	intake, physical This FOA is through an obesity- y be available if FOA are not months of the



SPIN ID Program Title		Sponsor Name	Sponsor Numb	per Deadline Date	Funding Amount
	beyond that timeline. This Notice of Fur	nding Opportunity (NOFO) require	es a Plan for Enh	nancing Diverse Perspe	ctives (PEDP).
124852 Developmental AIDS Research Ce (P30 Clinical Trial Optional)	nters on Mental Health and HIV/AIDS	National Institute of Mental Health/NIH/DHHS	PAR- 24-164	26-Jul-2025 [Optional][LOI/Pre- App]	3,000,000 USD
Contact Name	Christopher Gordon, PhD				
Contact Telephone	240-627-3867				
Contact Email	cgordon1@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	26-Jul-2025 [Optional][LOI/Pre-App], 25	-Aug-2025 , 26-Jul-2026 [Optiona	l][LOI/Pre-App]	, 25-Aug-2026	
Synopsis	The National Institute of Mental Health grants (P30) to support Developmental support that facilitates the developmen mission. This Funding Opportunity Annotareas, including basic, NeuroHIV, behav implementation science. The intent of D successfully for a full NIMH AIDS Resear	HIV/AIDS Research Centers (D-AR t of high impact science in HIV/AI ouncement (FOA) intends to supplioral and social, integrated biobel D-ARC support is that the propose	C). The D-ARC in DS and mental ort innovative, in navioral, applied doore activities	s intended to provide i health that is relevant interdisciplinary resear d, clinical, translational	nfrastructure to the NIMH ch in several , and
124853 NIMH AIDS Research Center on M Trial Optional)	lental Health and HIV/AIDS (P30 Clinical	National Institute of Mental Health/NIH/DHHS	PAR- 24-165	26-Jul-2025 [Optional][LOI/Pre- App]	7,500,000 USD
Contact Name	Christopher Gordon, PhD				
Contact Telephone	240-627-3867				
Contact Email	cgordon1@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	26-Jul-2025 [Optional][LOI/Pre-App], 25	5-Aug-2025 , 26-Jul-2026 [Optiona	l][LOI/Pre-App]	, 25-Aug-2026	

Synopsis The National Institute of Mental Health (NIMH) Division of AIDS Research (DAR) encourages applications for Center Core grants (P30) to support HIV/AIDS Research Centers (ARC). The ARC is intended to provide infrastructure support that

SPIN ID	Program Title		Sponsor Name	Sponsor Num	ber Deadline Date	Funding Amount
		facilitates the development of high imp Funding Opportunity Announcement (F including basic, NeuroHIV, behavioral a science.	OA) intends to support innovative	e, interdisciplina	ary research in several	areas,
125860 <u>N</u>	IINDS Research Education Oppor	tunities (R25 Clinical Trial Not Allowed)	National Institute of Neurologica Disorders and Stroke/NIH/DHHS	l PAR- 24-200	16-Jun-2025 [Optional][LOI/Pre- App]	1,250,000 USD
	Contact Name	Letitia Weigand, Ph.D.				
	Contact Telephone	301-496-4188				
	Contact Email	<u>DirectorOTWD@ninds.nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2025 [Optional][LOI/Pre-App], 1	.5-Jul-2025 , 15-Jun-2026 [Optiona	l][LOI/Pre-App], 14-Jul-2026	
	Synopsis	The NIH Research Education Program (overarching goal of this R25 program is workforce to meet the nation's biomed goal, this FOA will support creative edu Experiences The purpose of this funding continuation of nationally available new NINDS. The primary focus of programs provide research experience, an in-dep only possible from a nationally organize experience, programs must also include appropriate for this NOFO must include participants and an established applica	to support educational activities of lical, behavioral and clinical resear cational activities with a primary of group opportunity announcement is to proscience research education prosubmitted under this FOA should be the understanding of techniques, and program. Within the context of the immersive coursework and expert a nationwide recruitment process.	that compleme ch needs. To accous on: Course encourage appropriate on intensive nalytic approact gaining expertict discussion will	nt and/or enhance the complish the stated of es for Skills Development of the initial significantly advance thands-on experience thes and theory, and experience the primarily through the primarily through the propriete. Progressions	training of a ver-arching ent Research tion or the mission of that will expertise that is ands-on trams
128115 D	llueprint Neurotherapeutics Networks Networks Networks (New York New York N	work (BPN): Biologic-based Drug isorders of the Nervous System (U44	National Institute of Neurologica Disorders and Stroke/NIH/DHHS	I PAR- 24-294	15-Jun-2025 [Optional][LOI/Pre- App]	Not Specified
	Contact Name Contact Telephone	Lauren Friedman, Ph.D. 301-827-5065				



SPIN ID	Program Title		Sponsor Name	Sponsor Numbe	Deadline Date	Funding Amount	
	Sponsor Website	lauren.friedman@nih.gov Link to program URL					
	• • •		un-2025 [Optional][LOI/Pre-App], 15-Jul-2025, 16-Dec-2025 [Optional][LOI/Pre-App], 15-Jan-2026, 15-Jun-2026 tional][LOI/Pre-App], 15-Jan-2027, 15-Jun-2027 [Optional][LOI/Pre-App], 15-Jan-2027, 15-Jun-2027 [Optional][LOI/Pre-], 15-Jul-2027				
	Synopsis	The purpose of this Notice of Funding Opp development of diverse biotherapeutic mooligonucleotides, gene therapies, cell thera and neuromuscular system disorders. The provides support for biologics-based thera human clinical trials. This NOFO is a phase regular interactions with NIH program staff be conducted in their own laboratories and Participants may also augment their project specialize in manufacturing, nonclinical stuexisting intellectual property and are assignance.	odalities — including but not linapies, and other emerging ther Blueprint Neurotherapeutics New discovery and development d, milestone-driven cooperatives. Awarded projects will received assistance from NIH-funded cott through collaboration with Nadies, and early phase clinical trees.	nited to antibodie apeutic modalitie letwork for Biolog activities from le e agreement that e funding for invectonsultants with in IIH-funded contractals. Recipient ins	s, peptides, proteins of the treatment o	nt of nervous program ough first-in- poration and a activities to pry experience. tions that	
128113	Blueprint Neurotherapeutics Netwolscovery and Development for DUG3/UH3 Clinical Trial Optional)	isorders of the Nervous System	ational Institute of Neurologica sorders and Stroke/NIH/DHHS	I PAR- 24-293	5-Jun-2025 Optional][LOI/Pre- op]	Not Specified	
	Contact Telephone	lauren.friedman@nih.gov					

15-Jun-2025 [Optional][LOI/Pre-App], 15-Jul-2025, 16-Dec-2025 [Optional][LOI/Pre-App], 15-Jan-2026, 15-Jun-2026 Deadline Dates (ALL) [Optional][LOI/Pre-App], 15-Jul-2026, 16-Dec-2026 [Optional][LOI/Pre-App], 15-Jun-2027 [Optional][LOI/Pre-App]] App], 15-Jul-2027

Program URL Link to program URL

The purpose of this Notice of Funding Opportunity (NOFO) is to provide funding, resources, and expertise to accelerate the development of diverse biotherapeutic modalities — including but not limited to antibodies, peptides, proteins,

SPIN ID Program Title			Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		oligonucleotides, gene therapies, cell thera and neuromuscular system disorders. The provides support for biologics-based thera human clinical trials. This NOFO is a phased regular interactions with NIH program staff be conducted in their own laboratories and Participants may also augment their project specialize in manufacturing, nonclinical stu- existing intellectual property and are assig	Blueprint Neurotherapeutics Napy discovery and development d, milestone-driven cooperative ff. Awarded projects will received assistance from NIH-funded cot through collaboration with Nadies, and early phase clinical tr	etwork for Biologics activities from lead e agreement that interfer funding for investigations with industrials. Recipient instit	(BPN Biologics) poptimization throwolves close collab gator-led research ustry and regulatoresearch research organiza	orogram ough first-in- poration and n activities to ory experience. tions that
		r Davalanmant award (K) z _ (linical Trial	ational Institute of Neurologica isorders and Stroke/NIH/DHHS	I PAR- 24-220 12-J	un-2025	Not Specified
	Contact Name	Laura D. Wandner				
Con	tact Telephone					
	Contact Email	Laura.Wandner@nih.gov				
Sį	oonsor Website	Link to sponsor website				
	Program URL	Link to program URL				
Dead	line Dates (ALL)	12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 1 , 12-Nov-2026 , 12-Feb-2027 , 12-Mar-202		-Mar-2026 , 12-Jun-	2026 , 12-Jul-2020	6 , 12-Oct-2026
	Synopsis	The purpose of the NIH HEAL Initiative Pair Career Development award (K23) (Clinical doctoral degrees to create a group of new program will provide independent NIH rest independent research programs in areas suprogram. This Notice of Funding Opportuinvestigator of an independent clinical trial part of their research and career developmes research experience in a clinical trial led by	Trial Required) is to support the and well-trained, independent earch support during the early-upported by the NIH HEAL Initiality (NOFO) is designed specifically a clinical trial feasibility studyment. Applicants not planning a	e career developme investigators. This secareer phase to helpative's Clinical Reseasally for applicants per, or a separate ancil n independent clinical	nt of individuals was upervised career or recipients establarch in Pain Managaroposing to serve lary study to an exal trial, or propos	vith clinical development olish gement as the lead kisting trial, as
		cian Training Program (PCTP): Mentored Na vards (K08 - Clinical Trials Not Allowed) Di	ational Institute of Neurologica isorders and Stroke/NIH/DHHS	I PAR- 24-219	un-2025	Not Specified

SPIN ID	Program Title	 Sponsor Name	Sponsor Number	Deadline Date	Funding
SPIN ID	Frogram ritie	Sponsor Name	Sponsor Number	Deadine Date	Amount

Contact Name Laura D. Wandner

Contact Telephone

Contact Email Laura. Wandner@nih.gov

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL)

12-Jun-2025, 12-Jul-2025, 12-Oct-2025, 12-Nov-2025, 12-Feb-2026, 12-Mar-2026, 12-Jun-2026, 12-Jul-2026, 12-Oct-2026 , 12-Nov-2026 , 12-Feb-2027 , 12-Mar-2027 , 12-Jun-2027 , 12-Jul-2027

The purpose of this NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08 - Clinical Trials Not Allowed) is to support the career development of individuals with clinical doctoral degrees to create a group of new and well-trained, independent investigators. This supervised career development program will provide independent NIH research support during the early-career phase to help recipients establish independent research programs in areas supported by the NIH HEAL Initiative's Clinical Research in Pain Management program. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator should apply to the companion NOFO. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be related to the

programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Synopsis

NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored National Institute of Neurological Clinical Scientist Development Awards (K08 - Clinical Trials Required)

Disorders and Stroke/NIH/DHHS

PAR-24-217

12-Jun-2025

Not **Specified**

Contact Name Laura D. Wandner

Contact Telephone

Contact Email Laura. Wandner@nih.gov



126806

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		I				
	·	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Jun-2025 , 12-Jul-2025 , 12-Oct-2025 , 12-Nov-2026 , 12-Feb-2027 , 12-Mar-2		2-Mar-2026 , 12-Jun	-2026 , 12-Jul-202	6 , 12-Oct-2026
	Synopsis	The purpose of this NIH HEAL Initiative Awards (K08) (Clinical Trials Required) is create a group of new and well-trained, independent NIH research support during areas supported by the NIH HEAL Init Opportunity (NOFO) is designed specific clinical trial, a clinical trial feasibility stucareer development. Applicants not plackinical trial led by another investigator,	s to support the career developm independent investigators. This ng the early-career phase to help iative's Clinical Research in Pain I cally for applicants proposing to s dy, or a separate ancillary study to nning an independent clinical tria	nent of individuals we supervised career do recipients establish Management prograserve as the lead investo an existing trial, and or proposing to gal, or proposing to gal,	ith clinical doctora evelopment progrant independent resement. This Notice of Festigator of an indesement of their resement.	I degrees to am will provide earch programs funding ependent arch and
128003	Blueprint Neurotherapeutics Networks of Discovery and Development of Discovery and Clinical Trial Optional)	work (BPN): Small Molecule Drug sorders of the Nervous System	National Institute of Neurologica Disorders and Stroke/NIH/DHHS	15-	Jul-2025	Not Specified
	Contact Name	Charles Cywin, PhD				
	Contact Telephone	301-496-1779				
	Contact Email	charles.cywin@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jul-2025 , 18-Aug-2025 , 15-Jan-2026	6 , 17-Apr-2026 , 15-Jul-2026 , 18	-Aug-2026		
	Synopsis	The Blueprint Neurotherapeutics Network advance their small molecule drug disconfor conducting all studies that involve do for all activities to be conducted in their consultants and can augment their projechemistry, pharmacokinetics, toxicology Practices (GMP), and Phase I clinical test Discovery phase the goal is to character	overy and development projects is isease- or target-specific assays, own laboratories. In addition, ap ect with NIH contract research or y, formulations development, che ting. Projects can enter either at	into the clinic. Partic models, and other re pplicants will collabor rganizations (CROs) t emical synthesis incl the Discovery or the	ipants in the BPN a esearch tools and r orate with NIH-fund that specialize in m uding under Good e Development stag	are responsible receive funding ded redicinal Manufacturing ge. In the

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	structure activity relationships (SAR) ar as metabolism, selectivity, toxicity, etc. development candidate through Invest Projects can enter the program at the I and phase I clinical testing. BPN recipie assignment of IP rights from the BPN conegotiations) for drug candidates deve	As projects enter or advance to the igational New Drug (IND)-enabling Development stage and progress in the interestinations retain their assignment ractors and consultants (and the image).	he Development sta g toxicology studies n a shorter period to ment of intellectual	ge the goal is to a and phase I clinica IND enabling tox property (IP) right	dvance a single all testing. icology studies and gain
114328 Advanced-Stage Development and for Interdisciplinary Aging Studies	d Utilization of Research Infrastructure (R33 Clinical Trial Optional)	National Institute on Aging/NIH/	DHHS PAR- 02	Jul-2025	2,499,995 USD
Contact Name	Dr. Sanoj Suneja				
Contact Telephone	301-402-7710				
Contact Email	sunejas@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	02-Jul-2025 , 03-Nov-2025				
Synopsis	This Funding Opportunity Announceme and utilization of novel research infrast partnerships or collaborations. This FO support for expanded activities. Applica or non-NIH support. Through this awar infrastructure to support projects that	ructure to advance the science of A utilizes NIH's R33 Exploratory/D ants are expected to have an exist d, investigators will endeavor to d	aging in specific are evelopmental Grant ing research infrastr evelop a mature and	eas requiring interous Phase II activity Fucture developed d sustainable rese	disciplinary code to provide with other NIH
114327 Research Infrastructure Developm (R61/R33 - Clinical Trial Optional)	nent for Interdisciplinary Aging Studies	National Institute on Aging/NIH/	DHHS PAR- 02	Jul-2025	2,499,995 USD
Contact Name	Dr. Sanoj Suneja				
Contact Telephone	301-402-7710				
Contact Email	sunejas@mail.nih.gov				



Sponsor Website

Program URL Link to program URL
Deadline Dates (ALL) 02-Jul-2025 , 03-Nov-2025

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	This Funding Opportunity Announcement that will advance the science of aging is utilizes NIH's R61/R33 Exploratory/Devisupport for initial developmental active this award, investigators will endeavor interdisciplinary aging research questions.	n specific areas requiring interdist relopmental Phased Award activitities. The R33 phase provides up to to develop a sustainable research	ciplinary partnership y code. The R61 pha o 3 years of support	s or collaborations se provides up to 2 for expanded acti	s. This FOA 2 years of vities. Through
123977	NIA Career Transition Award (K22	Independent Clinical Trial Not Allowed	National Institute on Aging/NIH	/DHHS PAR- 12 24-120	Jun-2025	Not Specified
	Contact Name	Jamie Lahvic, Ph.D.				
	Contact Telephone					
	Contact Email	NIATraining@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Jun-2025 , 12-Jul-2025 , 12-Oct-202	5 , 12-Nov-2025			
	Synopsis	The purpose of the NIA Career Transiti tenure-track or equivalent faculty posi provide postdoctoral phase funding; the faculty positions within 12 months after position at an extramural institution/o salary and research support. This Notice research that does not involve leading	tions conducting research that ad nerefore, candidates should be preer confirmation of a positive fundi rganization, the award will provid se of Funding Opportunity (NOFO)	vances the mission of epared to transition to ng decision. After tra e three years of protons is designed specifica	f NIA. This award to tenure-track or insition to an apprected research tinally for candidates	does not equivalent oved faculty ne through proposing
	Aging Research Dissertation Awar <u>Frial Not Allowed)</u>	ds to Promote Diversity (R36 Clinical	National Institute on Aging/NIH	/DHHS PAR- 24-130 16-	Jun-2025	Not Specified
	Contact Name	Jamie Lahvic, Ph.D.				
	Contact Telephone					
	Contact Email	NIATraining@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				



Deadline Dates (ALL) 16-Jun-2025, 16-Jul-2025, 16-Oct-2025, 16-Nov-2025, 16-Feb-2026, 16-Mar-2026, 16-Jun-2026, 16-Jul-2026, 16-Oct-2026

	9	••			
SPIN ID Program Title		Sponsor Name	Sponsor Numl	per Deadline Date	Funding Amount
Synopsis	, 16-Nov-2026 This Notice of Funding Opportunity (NO engaged in research on aging and agingwithin NIA's strategic priorities.				
120104 RFA-DA-25-063 Microglial Patho Disorder (SUD) and HIV (R61/R33	ophysiology in Comorbid Substance Use Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA- DA-25- 063	14-Jul-2025 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Tristan McClure-Begley, PhD				
Contact Telephone	301-451-1467				
Contact Email	tristan.mcclure-begley@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	14-Jul-2025 [Optional][LOI/Pre-App], 14	-Aug-2025			
Synopsis	The purpose of this notice of funding op HIV-infected microglia, and how these h cellular signaling in the context of como	ost-viral interactions contribute	to cell type- and	•	
	dies to Investigate Mechanisms of HIV	National Institute on Drug	RFA-	14-Jul-2025	3,500,000
121767 <u>Infection, Replication, Latency, an</u> <u>Substance Use Disorders (R01 Clir</u>		Abuse/NIH/DHHS	DA-25- 073	[Optional][LOI/Pre- App]	USD
Contact Name	Shang-Yi Anne Tsai, Ph.D.				
Contact Telephone	301-827-5842				
Contact Email	stsai@nih.gov				
Sponsor Website	Link to sponsor website				
Program URL	Link to program URL				
Deadline Dates (ALL)	14-Jul-2025 [Optional][LOI/Pre-App], 14	-Aug-2025			



This notice of funding opportunity (NOFO) will support high risk high impact studies that 1) develop or apply novel tools or

pathogenesis (including neuroHIV) in the context of Substance Use Disorders (SUDs). This initiative focuses on exploration

Synopsis technologies or 2) test novel hypotheses to investigate mechanistic questions in HIV infection, replication, latency, and/or

SPIN ID Program Title		Sponsor Name	Sponsor Num	ber Deadline Date	Funding Amount
	and characterization of signaling pathw promote milestone-driven research to i established, and maintained in the CNS size and persistence of CNS HIV reservo	nvestigate the underlying molecu and to determine how addictive s	lar mechanisms	s by which HIV infectio	n is initiated,
126998 Device Based Treatments for Substitution of Substitution (Substitution of Substitution	stance Use Disorders (UG3/UH3 Clinical	National Institute on Drug Abuse/NIH/DHHS	PAR- 25-023	14-Jul-2025 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Will M. Aklin, Ph.D				
Contact Telephone	301-827-5909				
Contact Email	aklinwm@nida.nih.gov				
Sponsor Website					
Program URL	<u>Link to program URL</u>				
Deadline Dates (ALL)	14-Jul-2025 [Optional][LOI/Pre-App], 13 [Optional][LOI/Pre-App], 13-Aug-2026	3-Aug-2025 , 18-Nov-2025 [Optior	nal][LOI/Pre-Ap _l	o], 18-Dec-2025 , 14-Ju	ıl-2026
Synopsis	The purpose of this notice of funding of Disorders (SUDs). The continuing advant or neurophysiological devices that are so in the FDA approval process, with the understand Applications may focus on the pre-clinical approved for other indications. Applications approved for other indications. Applications approved for other indications. The UC to be accomplished by the end of the processful completion of the UG3. UG3 National Institute on Drug Abuse and produces both UG3 and UH3 phases.	ces in technologies offer unprece rafe and effective SUD treatments Itimate goal of generating new, Fl cal and/or clinical development ar- tions may evaluate the mechanism G3 phase, for up to two years, is deriod. The UH3 phase is to provide projects that meet their mileston	dented opportu s. The objective DA approved de nd testing of ne m of action of a lesigned to supple e funding for up es will be admin	unities to develop neur is to move devices to te evice-based treatments w devices or existing d device. The UG3/UH3 port a project with spe to three additional year inistratively considered	comodulatory cheir next step is for SUDs. evices Cooperative cific milestones ears following by the
129136 RFA-DA-26-056 Accelerating the Existing Data (R21 Clinical Trial No.	e Pace of Substance Use Research Using ot Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA- DA-26- 056	18-Jun-2025 [Optional][LOI/Pre- App]	400,000 USD
Contact Name Contact Telephone	Marsha F. Lopez, Ph.D., M.H.S. 301-443-6504				



SPIN ID Program Title		Sponsor Name	Sponsor Number	Pr Deadline Date	Funding Amount
Contact	Email marsha.lopez@nih.gov				
Sponsor We	ebsite				
Progran	n URL <u>Link to program URL</u>				
Deadline Dates	18-Jun-2025 [Optional][LOI/Pre-App], 17 (ALL) [Optional][LOI/Pre-App], 17-Jul-2026 , 03 App], 15-Jul-2027 , 03-Nov-2027 [Option	3-Nov-2026 [Optional][LOI/Pre-		•	
Syn	The purpose of this notice of funding opposts social science, behavioral, administrative behaviors (defined as alcohol, tobacco, puse and HIV, and health service utilization based or clinical datasets to their full pot behaviors and their consequences include psychopathology, strategies to guide the efficient services for the prevention and for applications in response to this NOFC	e, and neuroimaging data to stu prescription, and other substan- in. This NOFO encourages the a cential in order to increase our ling morbidity and mortality, rist development, testing, implem treatment of substance use dis	dy the etiology an ces) and related di nalyses of public u knowledge of etiol k and resilience in entation, and deliv	d epidemiology of su sorders, prevention of se and other extant of ogy, trajectories of so the development of very of high quality, e	bstance using of substance community-ubstance using
129134 RFA-DA-26-055 Acceleration Existing Data (R01 Clinical Tr	ng the Pace of Substance Use Research Using ial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	DA-26- [.8-Jun-2025 Optional][LOI/Pre- App]	Not Specified
Contact I	Name Marsha F. Lopez, Ph.D., M.H.S.				
Contact Telep	hone 301-443-6504				
Contact	Email <u>marsha.lopez@nih.gov</u>				
Sponsor We	ebsite				
Progran	n URL <u>Link to program URL</u>				
Deadline Dates	18-Jun-2025 [Optional][LOI/Pre-App], 17 (ALL) [Optional][LOI/Pre-App], 17-Jul-2026 , 03 App], 15-Jul-2027 , 03-Nov-2027 [Option	3-Nov-2026 [Optional][LOI/Pre-			



The purpose of this notice of funding opportunity (NOFO) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This NOFO encourages the analyses of public use and other extant community-

SPIN ID Program Title		Sponsor Name	Sponsor Numb	per Deadline Date	Funding Amount
	based or clinical datasets to their full p behaviors and their consequences inclu psychopathology, strategies to guide the efficient services for the prevention and for applications in response to this NOI	uding morbidity and mortality, rine development, testing, implement of substance use di	isk and resilience i nentation, and del	n the development of ivery of high quality, e	ffective and
RFA-DA-24-007 Avenir Award F 113798 Pharmacology of Substance Use Allowed)		National Institute on Drug Abuse/NIH/DHHS	RFA- DA-24- 007	08-Jul-2025 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Sam Ananthan, Ph.D.				
Contact Telephone	301-435-2199				
Contact Emai	sam.ananthan@nih.gov				
Sponsor Website	2				
Program UR	Link to program URL				
Deadline Dates (ALL) 08-Jul-2025 [Optional][LOI/Pre-App], 0	7-Aug-2025			
Synopsi	Avenir means future in French, and this investigators proposing highly innovatis addiction. The purpose of this award is required for an R01 grant, but who profield.	ve research in the area of chemi to support those in an early sta	istry and pharmac ge of their career	ology of substance use who may lack the prel	e disorders and iminary data
116449 RFA-DA-25-074 Ex Vivo Models and Addictive Substance Use (RO	for Studies at the Intersection of HIV 1 Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	RFA- DA-25- 074	13-Jul-2025 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Da-Yu Wu, PhD				
Contact Telephone	301-435-4649				
	I wudy@nida.nih.gov				
Sponsor Website					



Deadline Dates (ALL) 13-Jul-2025 [Optional][LOI/Pre-App], 13-Aug-2025

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Synopsis	This notice of funding opportunity (NO pathophysiological mechanisms under disorders (HAND) using ex vivo culturir	ying the interaction between add	ictive substances and	d HIV-associated r	eurological
127285 RFA-DA-25-024 High Priority HIV Clinical Trial Optional)	V and Substance Use Research (R01	National Institute on Drug Abuse/NIH/DHHS		ul-2025 tional][LOI/Pre-]	Not Specified
Contact Name	Richard A. Jenkins, Ph.D.				
Contact Telephone	301-443-1923				
Contact Email	jenkinsri@nida.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	14-Jul-2025 [Optional][LOI/Pre-App], 1 [Optional][LOI/Pre-App], 13-Aug-2026			-Feb-2026 , 14-Jul	-2026
Synopsis	The purpose of this notice of funding of substance use. This NOFO invites researed avenues for prevention, treatment under this NOFO are required to have substance use. This initiative is open to epidemiologic, clinical, intervention, and use disorders (SUDs). The proposed resupportunity (NOFO) requires a Plan for	trch projects with the potential to t and cure of HIV among people was a detailed research plan, preliminal b both individual researchers and r and implementation research relate search areas must align with the N ties and Guidelines for Determinir	open new areas of F who use addictive sub- ary data, and a clear research teams. It ad ed to HIV in people w IIH's HIV/AIDS Resea ng HIV/AIDS Funding.	IIV/AIDS research istances. Applicating description of the dresses basic scien ith substance userch Priorities: NO	and/or lead to ions submitted nexus with nce, and substance
127413 NIDA Animal Genomics Program (U01 – Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR- 24-269 23-J	ul-2025	Not Specified
Contact Name	Amy C. Lossie, PhD		-		
Contact Telephone	301-827-6092				
Contact Email	lossieac@mail.nih.gov				
Sponsor Website					



Program URL Link to program URL

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL) Synopsis	23-Jul-2025 , 11-Feb-2026 , 23-Jul-2026 The purpose of the National Institute or molecular (epi)genetic variants that unce trajectory and SUD comorbidities. This compared to neural circuit function and behavior, that contribute to the genetic architectus structural variants, and all types of moband/or artificial intelligence/machine leand/or uncover the function of known ovariant identification at the circuit level cells. NIDA expects these studies to unce and inform future studies about potentic (NOFO) requires a Plan for Enhancing Dispersional control of the purpose o	n Drug Abuse (NIDA) Animal General relie neural and behavioral procession procession of the application of neuroscier over novel mechanisms that control of the procession of	esses and phenotype at links genetic, geno any type of genomi- nucleotide variants (ations that take geno multi-level 'omics d igenetic variants. Ot nce to variant identifations	es relevant to SUD omic and molecula c and/or epigenor SNVs), indels, larg omics, multi-omics ata, delineate gen her areas of interefication studies in ges across the SUD	risk, the SUD or mechanisms nic variants e and small s, data-based, e networks, est include tissues and D trajectory
1/43/4	Developing Digital Therapeutics for Clinical Trial optional)	or Substance Use Disorders (UG3/UH3	National Institute on Drug Abuse/NIH/DHHS	PAR- 24-064	lul-2025	Not Specified
	Contact Name	Will M. Aklin, Ph.D.				

Contact Telephone 301-827-5909

Contact Email aklinwm@nida.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 17-Jul-2025, 19-Nov-2025, 26-Mar-2026, 17-Jul-2026, 19-Nov-2026

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of Digital Therapeutics (DTx) to treat Substance Use Disorders (SUDs). Advances in technology offer unprecedented opportunities to develop clinical-grade mobile, web, or other software-based platforms designed to deliver treatments that are safe and effective for SUD. FDA authorization of DTx can play an important role in increasing the availability of treatments to patients with SUD. The primary objective of this FOA is to move DTx to their next step in the development process, with the ultimate goal of generating new, FDA authorized, disseminated treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new DTx or existing DTx developed for other indications. The UG3/UH3 Cooperative Agreement involves 2 phases. The UG3 phase, for up to 2 years, is designed to support a project with specific milestones to be accomplished by the end of the period. The UH3 phase is to provide funding for up to 3 additional years following successful completion of the UG3. UG3 projects that meet their milestones will be administratively considered by NIDA and prioritized for transition to the

SPIN ID Program Title		Sponsor Name	Sponsor Num	ber Deadline Date	Funding Amount
	UH3 phase. Investigators submitting to	o this FOA must address both UG3	3 and UH3 phase	S.	
Functional Validation and/or 113957 Implicated in Substance Use I Allowed)	Characterization of Genes or Variants Disorders (R21/R33 Clinical Trial Not	National Institute on Drug Abuse/NIH/DHHS	PAR- 24-267	28-Jul-2025	Not Specified
Contact Teleph Contact E Sponsor Wel	URL Link to program URL ALL) 28-Jul-2025 The purpose of this initiative is to supp		date and/or cha	racterize genes or varia	ants involved in
113177 Grand Opportunity in Medica Disorders (U01 Clinical Trial C	tions Development for Substance-Use ptional)	National Institute on Drug Abuse/NIH/DHHS	PAR- 25-328	12-Jul-2025 [Optional][LOI/Pre- App]	15,000,000 USD
Contact Teleph Contact E Sponsor Wel Program	URL Link to program URL ALL) 12-Jul-2025 [Optional][LOI/Pre-App], 1 The National Institute on Drug Abuse (Substance Use Disorders (SUDs) by end	NIDA) seeks to accelerate the dev couraging research applications to nedication studies that will have h	o support a diver	rse array of preclinical	and/or clinical
113173 Development of Medications and Overdose (UG3/UH3 - Cli	to Prevent and Treat Opioid Use Disorders nical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR- 25-329	12-Jul-2025 [Optional][LOI/Pre- App]	15,000,000 USD

SPIN ID Program Title		Sponsor Name	Sponsor Numb	per Deadline Date	Funding Amount
Contact Contact Tele Contact Sponsor W Prograt Deadline Dates	m URL Link to program URL s (ALL) 12-Jul-2025 [Optional][LOI/Pre-App], 2 The National Institute on Drug Abuse nopsis and treat opioid use disorder (OUD) a	11-Aug-2025 (NIDA) seeks research for the discov	very and develo	opment of medication	s to prevent
124237 across the Lifespan to Unde	overdose. (INvestigation of Co-occurring conditions erstand Down syndromE) Predoctoral to ion Award (F99/K00 Clinical Trial Not Allowed	National Institutes of Health/DHF	RFA- IS OD-24- 007	01-Jul-2025	Not Specified
	Name Sujata Bardhan, M.S., Ph.D.				
	phone 301-435-0471				
	Email sujata.bardhan@nih.gov				
Sponsor W					
_	m URL Link to program URL				
Deadline Date:	s (ALL) 01-Jul-2025 , 01-Jul-2026				_
Sy	The purpose of the INvestigation of Co (INCLUDE) Predoctoral to Postdoctoral broad variety of research fields to pur students from disciplines including, bu and neurobiology are invited to apply INCLUDE Program Staff prior to initiat does not allow applicants to propose to experience in a clinical trial led by a sp	Il Fellow Transition award (F99/K00) rsue postdoctoral training focused out not limited to, genetics, biochemic to this opportunity. Prospective application submission to lead an independent clinical trial,	is to recruit ex in Down syndro stry, data scien blicants are stro . This Funding (ceptional graduate stume related research. ce, imaging, engineeri ngly encouraged to co Opportunity Announce	udents from a Graduate ing, ontact the ement (FOA)
125358 Global Infectious Disease Roon Optional)	esearch Training Program (D43 Clinical Trial	National Institutes of Health/DHF	IS PAR- 24-174	07-Jul-2025 [Optional][LOI/Pre- App]	Not Specified



SPIN ID	Program Title		Sponsor Name	Sponsor Numb	er Deadline Date	Funding Amount
	Contact Telephone Contact Email Sponsor Website Program URL	sinab@mail.nih.gov Link to program URL 07-Jul-2025 [Optional][LOI/Pre-App], 06-A			· ·	(CID)
This Funding Opportunity Announcement (FOA) encourages joint applications for the Global Infectious Disease (GID) Research Training programs from low- and middle-income country (LMIC) and U.S. institutions. The application should propose a collaborative training program that will strengthen the capacity of a LMIC institution to conduct infectious or research (not including HIV/AIDS). FIC will support research training programs that focus on 1) major endemic or life-threatening emerging infectious diseases, 2) neglected tropical diseases, 3) infections that frequently occur as co-inference in HIV infected individuals or 4) infections or microbiomes associated with non-communicable disease conditions of pub synopsis health importance in LMICs. Advanced scientific training related to prevention, treatment or public health approaches technical area of basic, epidemiological, clinical, behavioral or social science health research may be supported. Reseat training programs should incorporate didactic, mentored research and professional development skills components to prepare individuals for sustainable careers that will have significant impact on the priority health research needs of LN This Notice of Funding Opportunity (NOFO) allows appointment of Trainees (D43) proposing to serve as the lead invest of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience clinical trial led by another investigator, as part of their research and career development.					n should ctious disease or life- co-infections in of public oaches to any l. Research nents to ds of LMICs.	
	FA-HG-23-018Investigator-Init quity (R21 Clinical Trial Optional)	iated Research in Genomics and Health	ational Institutes of Health/DH	HS HG-23-	08-Jun-2025 [Optional][LOI/Pre- App]	400,000 USD

Contact Name Lucia Hindorff, Ph.D.

Contact Telephone 240-271-1509

Contact Email hindorffl@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 08-Jun-2025 [Optional][LOI/Pre-App], 08-Jul-2025

Synopsis The purpose of this initiative is to support investigator-initiated research in genomics and health equity, with the ultimate



SPIN ID Program Title Sponsor Name Sponsor Number Deadline Date Amount
--

goal of developing approaches, generating and disseminating data, and implementing metrics or interventions that will advance the equitable use of genomics to improve health in U.S. populations. Awardees will conduct innovative and generalizable research in genomics and health equity spanning across genomic research areas and will incorporate a plan for enhancing diverse perspectives. This R21 Notice of Funding Opportunity (NOFO) will support small research projects that can be carried out in a short period of time with limited resources. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Applications supporting New or Early Stage Investigators from diverse backgrounds, including those from groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce, as described in the NIH Notice of Interest in Diversity (NOT-OD-20-031), are encouraged. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications without a PEDP will not be reviewed.

RFA-HG-23-017 -- Investigator-Initiated Research in Genomics and Health Equity (R01 Clinical Trial Optional)

National Institutes of Health/DHHS

RFA-08-Jun-2025 HG-23-[Optional][LOI/Pre-017 App]

2,500,000 USD

Contact Name Lucia Hindorff, Ph.D.

Contact Telephone 240-271-1509

Contact Email hindorffl@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 08-Jun-2025 [Optional][LOI/Pre-App], 08-Jul-2025

The purpose of this initiative is to support investigator-initiated research in genomics and health equity, with the ultimate goal of developing approaches, generating and disseminating data, and implementing metrics or interventions that will advance the equitable use of genomics to improve health in U.S. populations. Awardees will conduct innovative and generalizable research in genomics and health equity spanning across genomic research areas and will incorporate a plan for Synopsis enhancing diverse perspectives. Applications supporting New or Early Stage Investigators from diverse backgrounds, including those from groups traditionally underrepresented in the biomedical, behavioral, and clinical research workforce, as described in the NIH Notice of Interest in Diversity (NOT-OD-20-031), are encouraged. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications without a PEDP will not be reviewed.

124567 RFA-MD-2D-24-007 -- Technologies for Improving Minority Health and

National Institutes of Health/DHHS

RFA-

11-May-2025

Not



		a				
SPIN ID	Program Title	Spo	onsor Name	Sponsor Number	Deadline Date	Funding Amount
<u> </u>	Eliminating Health Disparities (R4	1/R42- Clinical Trial Optional)		MD-24- [Op	tional][LOI/Pre- b]	Specified
	Contact Name	LCDR Michael Banyas, USPHS, MPA				
	Contact Telephone	240-619-9483				
	Contact Email	nimhdsbirsttr@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-May-2025 [Optional][LOI/Pre-App], 10-Jun-May-2026 [Optional][LOI/Pre-App], 10-Jun-202				
	Synopsis	This Funding Opportunity Announcement (FOA Business Technology Transfer (STTR) grant app commercialization with the aim of improving none or more NIH-defined populations that expansional and culturally acceptable.	lications that propose to only innority health and/or red	develop a product, plucing and ultimately	rocess or service feliminating healt	or h disparities ir
1/3/9/1	NCCIH Natural Product Early Phas (R61/R33 Clinical Trial Required)	<u>e Clinical Trial Phased Innovation Award</u> Nation	al Institutes of Health/DF	PAR- 25-269 23-J	Jun-2025	1,750,000 USD
	Contact Name	Sekai Chideya, M.D., MPH				
	Contact Telephone	301-827-1916				
	Contact Email	sekai.chideya@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	23-Jun-2025 , 17-Jul-2025 , 23-Feb-2026 , 17-N	lar-2026 , 20-Oct-2026 , 1	3-Nov-2026		
	Synopsis	This Funding Opportunity Announcement (FOA of natural products (i.e., botanicals, dietary supfurther clinical testing. Under this FOA, trials minformation of high scientific utility and will supflie FOA will provide up to three years (R61 ph	oplements, and probiotics tust be designed so that re oport decisions about furt), which have a stron esults, whether posit her development or	ig scientific premisive or negative, w testing of the nat	se to justify ill provide ural product.

bioavailability, and assessment of the natural product's effect (i.e., measure of mechanism of action) when used by humans on a biological signature(s). If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding
5. IIV 12		Sponsor Hame	Sponsor Humber	Deadine Date	Amount

be awarded to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications are encouraged to design R33 studies to determine how to optimize the impact of the natural product on the biological signature by optimizing the delivery of the natural product by examining different doses or formulation. In addition, applications can be designed to combine the natural product with another treatment approach that is known to impact the same biological signature; or study the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R61/R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or effectiveness trials, nor will it support trials to test natural products for the treatment or prevention of cancer. A maximum of 5 years will be supported by the two phases of the R61/R33 award. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial 123784 Required)

National Institutes of Health/DHHS

PAR-23-Jun-2025 25-270

1,050,000 USD

Contact Name Sekai Chideya, M.D., MPH

Contact Telephone 301-827-1916

Contact Email sekai.chideya@nih.gov

Sponsor Website Link to sponsor website

Program URL

Deadline Dates (ALL) 23-Jun-2025, 17-Jul-2025, 23-Feb-2026, 17-Mar-2026, 20-Oct-2026, 13-Nov-2026

This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. Synopsis This FOA will provide up to 3 years support for studies to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications are encouraged to design studies to determine how to optimize the impact of the natural product on the biological signature by optimizing the delivery of the natural product by examining different doses or formulations. In addition, applications can be designed to combine the

						Funding
SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Amount
		natural product with another treatmen of the natural product in a target popul be hypothesis based, milestone-driven, mechanism is intended to accelerate the stage clinical testing to determine where effectiveness trials, nor will it support t	ation that is more responsive. Cli and directly related to the resease the translation of emerging basic so ther continued clinical research is	nical trials submitted rch priorities and mis cience findings about warranted. This FOA	I under this FOA a ssion of NCCIH. Th t natural products A will not support	re expected to his R33 funding into early efficacy or
1 / / / / / -	sessment of Climate at Instituti lowed)	ons (ACt) Award (RC2 - Clinical Trial Not	National Institutes of Health/DH	PAR- 24-038 01	Jul-2025	1,250,000 USD
	Contact Name	H. Nelson Aguila, D.V.M.				
	Contact Telephone	240-276-6170				
	Contact Email	aguilah@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2025 , 20-Jan-2026 [Optional][LC	OI/Pre-App], 01-Jul-2026			
	Synopsis	The objective of this Notice of Funding assessments using validated survey instretention, and advancement of faculty, (see NIH Interest in Diversity). The plan attitudes, and concerns, about, for example should provide a foundation for the development of the development.	truments and to develop action p including those from groups und s for self-studies should lead to in mple, inequities, micro-aggression velopment of an action plan to en	lans for positive char errepresented in bio estitutional culture cl ns, institutional racis whance diversity, equ	nge in the recruitr medical and beha nange by identifyi m, and bias. The s	ment, hiring, avioral research ng perceptions, self-studies
119015	ative American Research Center otional)	s for Health (NARCH) (S06 Clinical Trial	National Institutes of Health/DH	PAR- 08 23-166	Jul-2025	6,500,000 USD
	Contact Name	Sheila A. Caldwell, PhD				
	Contact Telephone					
	Contact Email	caldwells@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Jul-2025 , 07-Aug-2025 , 08-Jul-2026	5 , 07-Aug-2026			



SPIN ID Program Title		Sponsor Name	Sponsor Numl	per Deadline Date	Funding Amount
Synops	The purpose of the Native American Re Indian/Alaska Native (AI/AN) tribes, trib eligible AI/AN tribal entities) to support enhancement activities.	pal colleges or universities, tribal he	ealth programs	, or tribal organizatior	s (collectively,
117066 <u>Instrumentation Grant Program</u> <u>Clinical Trial Not Allowed)</u>	for Resource-Limited Institutions (S10 -	National Institutes of Health/DHF	PAR- 23-138	03-Jul-2025	250,000 USD
Contact Nam	Dorothy Beckett, PhD				
Contact Telephon	e				
Contact Ema	il dorothy.beckett@nih.gov				
Sponsor Websit	re				
Program UR	Link to program URL				
Deadline Dates (ALI	L) 03-Jul-2025				
Synops	The Instrumentation Grant Program for its instruments to enhance the research at support biomedical research and educations.	nd educational missions of resourc	e-limited instit	utions. Requested inst	ruments may
	ve Fellows: Ruth L. Kirschstein National Individual Postdoctoral Fellowship (F32)	National Institutes of Health/DHF	RFA- IS MH-23- 110	12-Jul-2025 [Optional][LOI/Pre- App]	Not Specified
Contact Nam	e Ashlee Van't Veer, PhD				
Contact Telephon	e 301-443-3107				
Contact Ema	il Brain.Initiative.Training@nih.gov				
Sponsor Websit	e				
Program UR	RL Link to program URL				
Deadline Dates (ALI	L) 12-Jul-2025 [Optional][LOI/Pre-App], 1:	I-Aug-2025			
Synops	The purpose of the Brain Research thro program is to enhance the research tra the potential to become productive inv Applications are encouraged in any rese	ining of promising postdoctorates of estigators in research areas that w	early in their po ill advance the	ostdoctoral training pe goals of the BRAIN Ini	eriod, who hav tiative.



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	-------------------

expected to propose research training in an area that clearly complements their predoctoral research. Formal training in analytical tools appropriate for the proposed research is expected to be an integral component of the research training plan. In order to maximize the training potential of the F32 award, this program encourages applications from individuals who have not yet completed their terminal doctoral degree and expect to do so within 12 months of the application due date. On the application due date, candidates may not have completed more than 12 months of postdoctoral training. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored

126793 Clinical Scientist Development Awards (K08 - Basic Experimental Studies with Humans (BESH) Required)

National Institutes of Health/DHHS

PAR-24-218 12-Jun-2025 Not Specified

Contact Name Laura D. Wandner

Contact Telephone

Contact Email <u>Laura.Wandner@nih.gov</u>

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL)

12-Jun-2025, 12-Jul-2025, 12-Oct-2025, 12-Nov-2025, 12-Feb-2026, 12-Mar-2026, 12-Jun-2026, 12-Jul-2026, 12-Jul-2026, 12-Nov-2026, 12-Feb-2027, 12-Jul-2027, 12-Jul-2027

The purpose of this NIH HEAL Initiative PainCare Clinician Training Program (PCTP): Mentored Clinical Scientist Development Awards (K08) (BESH) is to support the career development of individuals with clinical doctoral degrees to create a group of new and well-trained, independent investigators. This supervised career development program will provide independent NIH research support during the early-career phase to help awardees establish independent research programs in areas supported by the NIH HEAL Initiative's Clinical Research in Pain Management program. This Parent Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as "prospective basic science studies involving human participants." These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO. The proposed project must be

related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their

Synopsis

SPIN ID Program Title			Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
		scientific missions. This Notice of Fund the lead investigator of an independent trial, as part of their research and caree experimental study with humans, or pro humans led by another investigator, mu	clinical trial, a clinical trial feasib r development. Applicants not pl posing to gain research experier	ility study, or a sepa anning an independ nce in a clinical trial b	rate ancillary stud ent clinical trial or pasic experimenta	y to an existing basic I study with	
	egnant and L	e to Conduct Innovative Research for actating Individuals, and Persons with al Optional)	National Institutes of Health/DH	PAR- 15- 25-311	Jul-2025	6,250,000 USD	
Co	ntact Name	Robert Tamburro, MD, MSc					
Contact	t Telephone	301-480-2619					
Co	ontact Email	NICHD-Network-ClinicalResearch@nih.	gov				
Spons	sor Website						
P	rogram URL	<u>Link to program URL</u>					
Deadline	Dates (ALL)	15-Jul-2025 , 14-Nov-2025 , 15-Mar-2026 , 15-Jul-2026 , 13-Nov-2026 , 15-Mar-2027 , 15-Jul-2027 , 15-Nov-2027					
	Synopsis	The purpose of this Notice of Funding C relevant to infants, children, women, promultisite, investigator-initiated clinical to milestone-driven mechanism consisting phase (UH3). Applications submitted in and UH3 phases. A UG3 project (phase prioritized for transition to the UH3 away network infrastructure as a platform for community. Applications must be submigrant applications in conjunction with the equivalent as determined by the NICHD Perspectives (PEDP).	regnant and lactating individuals, trials and observational studies. To fastart-up phase (UG3) and a response to this NOFO must add by that meets its milestones will be and (phase II). This NOFO provided investigator-initiated innovative itted as investigator-initiated, must respective NICHD-supported N	and persons with di his NOFO will utilize full enrollment and or ress specific aims an e administratively co s an opportunity to le hypotheses by any ulti-Project Director/ letwork Data Coordi	sabilities to condu a bi-phasic (UG3/ clinical study implo d milestones for b onsidered by NICH everage NICHD cli investigator in the Principal Investiga nating Center (DC	ict innovative, (UH3), ementation ooth the UG3 ID and inical research extramural ator (PD/PI)	
114250 Trailblazer Award for In Optional)	New and Ea	rly Stage Investigators (R21 Clinical Trial	National Institutes of Health/DH	PA-25- 169 07-	May-2025	400,000 USD	
		Randy King, Ph.D. 301-451-0707					

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
Contact Email Sponsor Website Program URL Deadline Dates (ALL) This Trailblazer Award is an opportunity for NIH-defined New and Early Stage Investigators (https://grants.nih.gov/policy/early-investigators/index.htm) to pursue research programs of high interest to the NIBI integrate engineering and the physical sciences with the life and/or biomedical sciences. A Trailblazer project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, disco driven, or hypothesis-driven. Importantly, applicants must propose research approaches for which there are minimal preliminary data. A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. Ho if available, minimal preliminary data are allowed. Preliminary data are defined as material which the applicant has independently produced and not yet published in a peer-reviewed journal.All preliminary data should be clearly mark limited to one-half page, which may include one figure. Applications including data more than one-half page or more one figure will be considered noncompliant with the FOA instructions and will not go forward to review.							
122317	Blueprint Neurotherapeutics Netv Discovery and Development for D Clinical Trial Optional)		Dliant with the FOA instructions and National Institutes of Health/DHF	ΡΔR-	d to review. Jul-2025	Not Specified	
	Contact Name Contact Telephone	Charles Cywin, PhD 301-496-1779 charles.cywin@nih.gov					
	Sponsor Website	-					
		15-Jul-2025, 18-Aug-2025, 15-Jan-202 The Blueprint Neurotherapeutics Netw advance their small molecule drug disc for conducting all studies that involve for all activities to be conducted in the	vork (BPN) invites applications from covery and development projects in disease- or target-specific assays, m	neuroscience invento the clinic. Particonodels, and other re	ipants in the BPN a esearch tools and r	are responsible eceive funding	

consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal

chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery or the Development stage. In the

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	----------------	---------------	-------------------

Discovery phase the goal is to characterize and optimize promising hit compounds using medicinal chemistry to establish structure activity relationships (SAR) and structure property relationships (SPR) including in vitro and in vivo properties such as metabolism, selectivity, toxicity, etc. As projects enter or advance to the Development stage the goal is to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects can enter the program at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN recipient Institutions retain their assignment of intellectual property (IP) rights and gain assignment of IP rights from the BPN contractors and consultants (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title		Sponsor Name	Sponso Numbe		adline te	Funding Amount
110556	Faculty Early Career Develop	oment Program	National Science Foundation	22-586	23-Jul-2025	400,0	000 USD
	Contact Name						
	Contact Telephone	703-292-5111					
	Contact Email	nsf-ccc@nsf.gov					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	23-Jul-2025					
	CAREER: The Faculty Early Career Development (CAREER) Program is a Foundation-wide activity that offers the Science Foundation's most prestigious awards in support of early-career faculty who have the potential to serv role models in research and education and to lead advances in the mission of their department or organization pursued by early-career faculty should build a firm foundation for a lifetime of leadership in integrating education research. NSF encourages submission of CAREER proposals from early-career faculty at all CAREER-eligible organization especially encourages women, members of underrepresented minority groups, and persons with disabilities to apply. PECASE: Each year NSF selects nominees for the Presidential Early Career Awards for Scientists and Enginger from among the most meritorious recent CAREER awardees.						ve as academic n. Activities ition and ganizations and o
130908	Incorporating Human Behav	ior in Epidemiological Models	National Science Foundation	25-538	14-Jul-2025	6,000	0,000 USD
	Contact Name Contact Telephone						
	·	zfeng@nsf.gov					
		Link to sponsor website					
	·	Link to program URL					
	Deadline Dates (ALL)						
	,	The Incorporating Human Behavior in Epidemiological Models (IHBEM) program supports research that incorporates social and behavioral processes in mathematical epidemiological models. The program provides support for projects that involve integrated participation from the mathematical and social, behavioral, and economic sciences.					



National Science Foundation (NSF) Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	---------------	--------------	-------------------	------------------	-------------------

SPIN ID	Program Title	Sponsor Na	me	Sponsor Number	Deadline Date	Funding Amount
126658	TTO (Tactical Technology Office)	Office Wide (OW) BAA	Defense Advanced Researc Agency/Department of Def	, HRUUTT	4S0023 20-Jun-	2025 Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	HR001124S0023@darpa.mil				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	20-Jun-2025				
	Synopsis	The DARPA Tactical Technology demonstrating revolutionary scales that demonstrate disrube manufactured responsively the nation's ability to rapidly Missionized Autonomy, Management of the property of the pr	platforms and systems with our platforms and systems with our place of the place of	cutting-edge technolog that reduce risk and c ting innovative execut e structures with the fo	y. TTO demonstrates co cost by managing comple ive summaries and prop ollowing focus areas: Pla	mpelling hardware at exity, and which can osals that enhance tform Innovation,
131226	Fiscal Year 2025 Rural Domestic V Sexual Assault, and Stalking Progr		Office on Violence Against Women/Department of Jus	o-OVW-2	2025-172287 08-Jul-2	950,000 USD
	Contact Name					
	Contact Telephone	202-307-6026				
	Contact Email	ovw.rural@usdoj.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Jul-2025 , 10-Jul-2025				
	Synopsis	The Rural Domestic Violence, rural victims of sexual assault address and prevent these cri prosecutors, victim service pr violence, dating violence, and in rural communities; or prog Tribes, local governments, an	, domestic violence, dating vi imes in rural areas. This prog oviders, and other related pa I stalking; treatment, advocad rams addressing sexual assau	olence, and stalking by ram supports cooperat arties to investigate and cy, counseling, legal ass alt. Eligible entities app	y supporting projects unitive efforts among law end prosecute sexual assausistance, or other victim licants are states and te	quely designed to nforcement officers, ilt, domestic services for victims rritories, Indian



SPIN ID	Program Title	Sponsor Name	Sponsor Nu	mber	Deadline Date	Funding Amount
130175	FCO U.S. Army Research Institu Social Sciences Broad Agency Ann (Fiscal Year 2026)	Dep	partment of the Army/Department Defense	W911NF-25-S-(0006 01-Jul-20	Not Specified
	Contact Name	Kimberly Wingert				
	Contact Telephone					
	Contact Email	kimberly.m.wingert.civ@army.mil				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2025				
	Synopsis	in behavioral science. It is issued u Regulation (FAR), which provides for the development of a specific sy U.S.C. 4001, 10 U.S.C. 4021, and 10 decades, the Army must improve individually and as part of a group: environments, and a wide spectrum complex, information-rich environ collaborate effectively in joint-serv will provide a scientific foundation areas for advancing personnel scienderiving valid measurements from Understanding dynamic restructure adaptation 3. Organizations and Sy Learning and Development: Holisti	cial Sciences (ARI) solicits new proponder the provisions of paragraph 6.1 for the acquisition of basic and applie stem or hardware procurement throw U.S.C. 4022. To meet the operation its capability to acquire, develop, emits capability to acquire, develop, emits of contexts; • Effectively function ments; • Perform in extended, hybritice and multi-national operations. A to support these broad capabilities. Ince. 1. Measurement of Individuals a complex assessments and continuous ing, coordination, and composition postems: Multilevel theory and methodic models of individual and collective an To be eligible for an award under	o2(d) (2) and 35 and research and bugh the comperal objectives of ploy, and retain lynamic mission autonomously and continuously and continuously and continuously and collectives: as streams of data orocesses in team ds for complex of learning and designed.	that part of develop titive selection of pr the U.S. Army over the Soldiers and leaders s, unpredictable ope and as part of larger us operations; • Inter cosals to conduct batch program focuse Advanced psychome ta 2. Teams and Sm ms and promoting of preganizations 4. For evelopment across we	Acquisition ment not related roposals and 10 the next two s who can erational systems in eract and sic research that es on four strategic etric theory for all Groups: ptimal team mal and Informal york settings and

certain minimum standards pertaining to financial resources and responsibility, ability to comply with the performance schedule, past performance, integrity, experience, technical capabilities, operational controls, and facilities. In accordance with Federal statutes, regulations, and Department of Defense (DoD) and Army policies, no person shall be excluded from participation in, be denied the benefits of, or be subjected to discrimination under any program or activity receiving financial

SPIN ID	Program Title	Sponsor Na	me	Sponsor Nu	mber	Deadline D	Date Fund	ding Amount
		assistance from the Army on a White paper submissions must be received (Questions): General question kimberly.m.wingert.civ@army technical POC. All questions refebruary 2025.	of the received by: 5:00 PM/13 by: 5:00 PM/1700 Eastern Down regarding white papers muy.mil. Questions about a specific paper as pecific paper by.mil.	700 Eastern S Daylight Time ust be submit cific research	tandard Time (E (EDT) on 1 July ted in writing to topic area must	EST) on 9 M 2025 2025 Dr. Kimber be submitt	arch 2025 Pro Response Dat rly Wingert, ted in writing	oposal es to the listed
131186	<u>Duchenne Muscular Dystrophy Re</u> <u>Clinical/Translational Research Av</u>		Department of the Army/D of Defense	epartment	HT942525DMD	RPCIRA	25-Jul-2025 [LOI/Pre-App]	Not Specified
	Contact Name							
	Contact Telephone	301-682-5507						
	Contact Email	help@eBRAP.org						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	25-Jul-2025 [LOI/Pre-App], 08	-Aug-2025					
	Synopsis	The fiscal year 2025 (FY25) Du (CTRA) mechanism supports a Duchenne muscular dystroph focus areas. Research projects and nonambulatory individua published data relevant to DN correlative studies to better if funding levels: Funding Level support larger, more complex must be an independent, earl time of application submission explained in the application. It collaboration between clinica Programs (CDMRP) expects to cost caps of \$0.65M for Fundi Funding Level 2 with a PPIO. To	dvanced translational researly (DMD) research into clinicals investigating therapies that its, are strongly encouraged. If the support the proposed inform development of drugs, it to support smaller, less conspreciping and/or clinical resultance investigator within in. Lapses in research time or it is encouraged, but not requil and nonclinical aspects of Devaluation allot approximately \$8.56 ming Level 1; \$0.75M for Funding	rch that will and applications to will be effications to will be effications to will be effications, devices, and mplex preclines arch. Early 10 years of the appointment wired, that the DMD research million (M) to ing Level 1 willing to will appoint to will application (M) to ing Level 1 willing to will application (M) to will applicate (M) to will	accelerate the mass. Research muss acious across the atures: Applicate ect. Pilot, prooffical and/or clinical	ovement of t address at e life span, i cions must i -of-principle tions are all cal research ng PI Optio appointme the biograp s an M.D. of onally Directely 5 CTRA SM for Fund	f promising id t least one of the least	eas in the FY25 CTRA hts, toddlers, inary and/or a, and TRA offers two g Level 2 to Partnering Pl ent) by the should be to increase Research with direct and \$1.35M for

SPIN ID	Program Title	Sponsor Na	sme Sponsor	Number	Deadline Date	Funding Amount
			el 2 is 4 years. It is anticipated that awa ch will expire for use on September 30, 26.			•
130173	U.S. Army Research Institute for t Sciences Broad Agency Announce (Fiscal Year 2026)		Department of the Army/Departmen of Defense	t W911NF25S000	06 01-Jul-20	25 Not Specified
	Contact Name	Dr. Kimberly Wingert				
	Contact Telephone					
	Contact Email	kimberly.m.wingert.civ@arm	<u>y.mil</u>			
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2025				
	Synopsis	Institute for the Behavioral are in behavioral science. It is issue Regulation (FAR), which prove to the development of a spectus. C. 4001, 10 U.S.C. 4021, and decades, the Army must imprindividually and as part of a genvironments, and a wide spectus.	ement (BAA) for the Foundational Scient and Social Sciences (ARI) solicits new produced under the provisions of paragraphides for the acquisition of basic and apprific system or hardware procurement than 10 U.S.C. 4022. To meet the operatorove its capability to acquire, develop, expounts Prepare for and adapt quickly to ectrum of contexts; Effectively function ts; Perform in extended, hybrid, and contents of contexts.	pposals for its fiscal 6.102(d) (2) and 35 blied research and hrough the compe- ional objectives of employ, and retain dynamic missions, a autonomously and	year 2026 program .016 of the Federal that part of develop titive selection of pr the U.S. Army over Soldiers and leaders unpredictable opera d as part of larger sy	of basic research Acquisition ment not related oposals and 10 the next two s who can ational estems in complex,
131172	<u>Duchenne Muscular Dystrophy Ro</u> <u>Development Award</u>	esearch ProgramIdea	Department of the Army/Departmen of Defense	t HT942525DMD	RPIDA 25-Jul-20 [LOI/Pre-	,
_	Contact Name					
	Contact Telephone	301-682-5507				
	Contact Email	help@eBRAP.org				
	Sponsor Website	Link to sponsor website				



Program Title Sponsor Name Funding Amount SPIN ID Sponsor Number Deadline Date Program URL Link to program URL Deadline Dates (ALL) 25-Jul-2025 [LOI/Pre-App], 08-Aug-2025 The fiscal year 2025 (FY25) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD). Applications should include a well1formulated, testable hypothesis based on strong scientific rationale. The FY25 DMDRP IDA mechanism has a New Investigator category for applicants early in their careers (i.e., within 10 years of their first faculty appointment or equivalent) or for established investigators new to DMD research. The New Investigator - Early Stage category is designed to allow applicants early in their faculty appointments to compete for funding Synopsis separately from established investigators. The New Investigator - Transitioning category is designed for investigators in an area other than muscular dystrophy, at or above the level of Assistant Professor, seeking to transition to a career in DMD, thereby bringing their expertise to the field. Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required. The Congressionally Directed Medical Research Programs (CDMRP) expects to allot approximately \$1.68 million (M) to fund approximately 3 Idea Development Award applications with direct cost caps of \$350,000. The maximum period of performance is 2 years. It is anticipated that awards made from this FY25 funding opportunity will be funded with FY25 funds, which will expire for use on September 30, 2031. Awards supported with FY25 funds will be made no later than September 30, 2026. Department of the Army/Department Rare Cancers Research Program--Resource and Community 01-Jul-2025 1,120,000 HT942525RCRPRCDA 131164 **Development Award** of Defense USD [LOI/Pre-App] Contact Name Contact Telephone 301-682-5507 Contact Email help@eBRAP.org Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 01-Jul-2025 [LOI/Pre-App], 06-Oct-2025 The fiscal year 2025 (FY25) Rare Cancers Research Program (RCRP) Resource and Community Development Award (RCDA) supports the development of research resources and clinical or preclinical data sets that will advance the field of rare cancers research and ultimately improve outcomes for individuals with rare cancers. Major gaps to be filled by this funding opportunity include: Lack of research and clinical resources, including patient tissues, cell, and tumor models. Lack of



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

communication and dissemination strategies within scientific and patient communities for sharing rare cancers research and clinical findings. Lack of infrastructure for sharing data and other resources. Lack of therapeutics and mechanistic research to inform treatment development. Distinctive Features: Engagement and partnerships with Patient Advocates must be integrated into the project from development of the research question through the execution of the study. Community building and enhancement are key components. Dissemination and sustainability of the platform for scientific and/or clinical, and patient community must be described. Preliminary data not required but may be included to address feasibility. Funding Details: (New for FY25) Funding limits are now listed as total cost limits, which is the combination of both direct and indirect costs. The Congressionally Directed Medical Research Programs (CDMRP) expects to allot approximately \$5.60 million (M) to fund approximately five Resource and Community Development Award applications with total cost caps of \$1.12M. The maximum period of performance is 4 years. It is anticipated that awards made from this fiscal year 2025 (FY25) funding opportunity will be funded with FY25 funds, which will expire for use on September 30, 2031. Awards supported with FY25 funds will be made no later than September 30, 2026.

131161 Rare Cancers Research Program--Concept Award

Department of the Army/Department of Defense

HT942525RCRPCA

22-Jul-2025 [LOI/Pre-App]

140,000 USD

Contact Name

Contact Telephone 301-682-5507

Contact Email help@eBRAP.org

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 22-Jul-2025 [LOI/Pre-App], 26-Aug-2025

The fiscal year 2025 (FY25) Rare Cancers Research Program (RCRP) Concept Award (CA) supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation in rare cancers. Applications must describe how the new idea will be innovative and present as a novel course of investigation in the field of rare cancers. Distinctive Features: Preliminary data are not required. Due to the blinded nature of the review process, identifying or making references to the Principal Synopsis Investigator (PI), collaborator(s), or their organization(s) in the proposal (Project Narrative, Supporting Documentations, Impact Statement, Justification Statement, and Statement of Work [SOW]) is prohibited and will result in administrative rejection of the application. (New for FY25) Funding limits are now listed as total cost limits, which is the combination of both direct and indirect costs. The Congressionally Directed Medical Research Programs (CDMRP) expects to allot approximately \$2.38M to fund approximately 17 Concept Award applications with total cost caps of \$0.14M. The maximum period of performance is 2 years. It is anticipated that awards made from this FY25 funding opportunity will be funded with FY25 funds,



SPIN ID	Program Title	Sponsor N	ame	Sponsor Numb	er Deadli	ne Date Fu	unding Amount
		-	September 30, 2031. Awards sarch must be relevant to activ	• •			•
131159	Rare Cancers Research Program-	-Idea Development Award	Department of the Army/D of Defense	Department HT	942525RCRPIDA	01-Jul-2025 [LOI/Pre-Ap	,
	Contact Name						
	Contact Telephone	301-682-5507					
	Contact Email	help@eBRAP.org					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	01-Jul-2025 [LOI/Pre-App], 0	6-Oct-2025				
	Synopsis	are still in the early stages of Distinctive Features: Applica discovery-driven research. P necessarily need to be derived have high potential impact of cost limits, which is the comprograms (CDMRP) expects the with total cost caps of \$0.49 FY25 funding opportunity wis supported with FY25 funds v	tare Cancers Research Program fedevelopment and have the partions are encouraged to including reliminary data with disease-sed from studies of the proposon rare cancers and the patient bination of both direct and including to allot approximately \$6.86N M. The maximum period of particular period	otential to yield de an explorator specific rationale ed rare cancer ty t community. (No direct costs. The late of the fund approximation of the late of late	impactful data and y aim or sub-aim to are required. Howe re(s)/subtype(s) ur ew for FY25) Fundir Congressionally Dir mately 14 Idea Dev rears. It is anticipate for use on Septem 5. The proposed rese	new avenues of support any new aver, these data ader study. Research limits are now ected Medical Relopment Awards and that awards aber 30, 2031. A	f investigation. ecessary a do not earch should w listed as total Research rd applications made from this
131150	FCOExponentiating Mathematic	cs (expMath)	Defense Advanced Researd Agency/Department of Def	· HK	001125S0010	08-Jul-2025	Not Specified
	Contact Name						
	Contact Telephone						
	Contact Email	expMath@darpa.mil					
	Sponsor Website	Link to sponsor website					



Program Title Sponsor Name Funding Amount SPIN ID **Sponsor Number Deadline Date**

Program URL Link to program URL

Deadline Dates (ALL) 08-Jul-2025

MATHEMATICS IS THE SOURCE OF SIGNIFICANT TECHNOLOGICAL ADVANCES; HOWEVER, PROGRESS IN MATH IS SLOW. Recent advances in artificial intelligence (AI) suggest the possibility of increasing the rate of progress in mathematics. Still, a wide gap exists between state-of-the-art AI capabilities and pure mathematics research. Advances in mathematics are slow for two reasons. First, decomposing problems into useful lemmas is a laborious and manual process. To advance the field of mathematics, mathematicians use their knowledge and experience to explore candidate lemmas, which, when composed together, prove theorems. Ideally, these lemmas are generalizable beyond the specifics of the current problem so they can be easily understood and ported to new contexts. Second, proving candidate lemmas is slow, effortful, and iterative. Putative proofs may have gaps, such as the one in Wiles' original proof of Fermat's last theorem, which necessitated more than a year of additional work to fix. In theory, formalization in programming languages, such as Lean, could help automate proofs, but translation from math to code and back remains exceedingly difficult. The significant recent advances in AI fall short of the automated decomposition or auto(in)formalization challenges. Decomposition in formal settings is currently a manual process, as seen in the Prime number theorem and beyond and the Polynomial Freiman-Ruzsa conjecture, with existing tools, such as Blueprint for Lean, only facilitating the structuring of math and code. Auto(in)formalization is an active area of research in the AI literature, but current approaches show poor performance and have not yet advanced to even graduatelevel textbook problems. Formal languages with automated theorem-proving tools, such as Lean and Isabelle, have traction in the community for problems where the investment in manual formalization is worth it. The goal of expMath is to radically accelerate the rate of progress in pure mathematics by developing an AI co-author capable of proposing and proving useful abstractions, expMath will be comprised of teams focused on developing AI capable of auto decomposition and auto(in)formalization and teams focused on evaluation with respect to professional-level mathematics. We will robustly engage with the math and AI communities toward fundamentally reshaping the practice of mathematics by mathematicians.

Synopsis

SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
131040	AAAAI Foundation Award to Su	stain Research Excellence	American Acader Immunology (AA	my of Allergy, Asthma & AAI)	06-May-202 [LOI/Pre-Ap	100 000 1180
	Contact Name	Katie Tetzlaff				
	Contact Telephone	414-272-6071				
	Contact Email	ktetzlaff@aaaai.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Jul-2025				
	Synopsis	This funding opportunity was creat academic journey. This award aims research programs, ensuring conting	to help investigato	rs maintain momentum as		
	Applicant Types					
	Funding Limit	100,000.00 maximum				
	Limited Submission	No				
130127	Meta Reality Labs Research Gra	a <u>nt</u>	American Acader	my of Optometry	11-Jul-2025	500,000 USD
	Contact Name					
	Contact Telephone	321-319-4870				
	Contact Email	FRLAAOF@aaoptom.org				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				



SPIN ID	Program Title	Sį	oonsor Name		Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	11-Jul-2025					
	Synopsis	pleased to annour investigations in tl	nce the application	is now open for a and the role visua	Indation (AAOF) and Meta a new grant opportunity for all experience plays in its o	ocused on stimulati	ng new
	Applicant Types						
	Funding Limit	500,000.00 maxim	num				
	Limited Submission	No					
083840 /	AATS Foundation Gardner Lectu	<u>ıreship</u>		American Associa Surgery	ation for Thoracic	02-Jul-202	5 10,000 USD
	Contact Name						
	Contact Telephone						
	Contact Email	foundation@aats.	org				
	Sponsor Website	Link to sponsor we	<u>ebsite</u>				
	Program URL <u>I</u>	<u>Link to program U</u>	<u>RL</u>				
	Deadline Dates (ALL)	02-Jul-2025					
	Synopsis (to honor his caree will bring a promir Sponsored and ad	r as a nationally-re nent AATS member	cognized cardiac lecturer to an AC AATS Foundation,	stablished by mentees, co surgeon and leader in car CGME-approved cardiotho the lectureship provides	diovascular medicin oracic surgery reside	e. This lectureship ncy institution.



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
	Applicant Types							
	Funding Limit 10,000.00 maximum							
	Limited Submission	No						
083815	Honoring Our Cleveland Clinic	Mentors Program	American Associa	ation for Thoracic	02-Jul-202	5 1,000 USD		
	Contact Name							
	Contact Telephone							
	Contact Email	foundation@aats.org						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	02-Jul-2025						
	Synopsis	The AATS Foundation Honoring Our Cleveland Clinic Mentors Program is for North American cardiothoracic surge residents in the chief/penultimate year of their training to participate in a full-day program at the Cleveland Clinic obtain a basic understanding of the steps necessary to secure their first full-time position following completion of their training, developing areas of expertise, and beginning their careers in an academic program. Successful applicants are invited to attend this valuable course and will be provided with a \$1,000 stipend to help cover their travel and hotel expenses. Participants are also welcome, but not obligated, to attend an evening reception preception program and a Grand Rounds Presentation/OR Observation following.						
	Applicant Types							
	Funding Limit	1,000.00 see detail						
	Limited Submission	No						



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
083812	Denton A. Cooley Fellowship		Amer Surge	ican Association for Thoracic ery	02-Jul-2025	5 5,000 USD			
	Contact Name								
	Contact Telephone								
	Contact Email	foundation@aat	s.org						
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	<u>URL</u>						
	Deadline Dates (ALL)	02-Jul-2025	Jul-2025						
	Synopsis	The American Association for Thoracic Surgery's Denton A. Cooley Fellowship provides an educational experience for North American cardiothoracic surgeons who are in the final year of their residency, or have recently completed their residency, to spend four weeks studying at the Texas Heart Institute (THI) and Baylor St. Luke's Medical Center (BSLMC). Annually, one recipient is selected and awarded a grant of \$5,000 to defray travel and living expenses. Additionally, recipients are strongly encouraged to attend the AATS Annual Meeting.							
	Applicant Types								
	Funding Limit	5,000.00 maxim	um						
	Limited Submission	No							
006566	Research and Training Scholars	<u>hips</u>		ican Association of Obstetricians Synecologists Foundation	01-Jul-2025	450,000 USD			
	Contact Name	William Catherin	no, MD, PhD Chair, AAOGF	Scholar Committee					
	Contact Telephone	301-295-3126							
	Contact Email	william.catherin	o@usuhs.edu						
	'								



SPIN ID Program Title	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
S	ponsor Website	Link to sponsor	website						
	Program URL	Link to program	<u> URL</u>						
Dead	lline Dates (ALL)	01-Jul-2025							
	Synopsis	Obstetrics and training. The Sc States or Canad talent, original translational re	ne AAOGF, the Foundation for SMFM, and ABOG seek to identify future academic physician leaders in the field of bestetrics and Gynecology and to stimulate their scholarly development through the support of advanced scientific aining. The Scholarship Award is to be used in an academic Department of Obstetrics and Gynecology in the United ates or Canada to provide research training and experience for a candidate of proven ability who exhibits significant lent, original thought, and evidence of dedication to an academic career. Research training may focus on basic or anslational research, disease pathogenesis, clinical diagnostics, interventions and prevention, epidemiology, and ealth services research.						
	Applicant Types								
	Funding Limit	150,000.00 per	year						
Lim	ited Submission	No							
087086 <u>Norton M. Ross</u>	s Award for Exce	ellence in Clinica	l Research	American Denta	l Association	07-Jul-202	5 5,000 USD		
	Contact Name								
Cor	ntact Telephone	312-440-2549							
	Contact Email	caap@ada.org							
S	ponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	<u>URL</u>						
Dead	lline Dates (ALL)	07-Jul-2025							



SPIN ID	Program Title	Sponsor Na	me	Sponsor Number	Deadline Date	Funding Amount		
	Synopsis	The Norton M. Ross Award for contributions in clinical investoral-dental diseases, as well honorarium and a plaque.	stigations that have adva	nced the diagnosis, treatm	ent, and/or prevent	ion of craniofacial-		
	Applicant Types	5						
	Funding Limit	5,000.00 see detail						
	Limited Submission	No						
048482	Pathway to Stop Diabetes - Acc	celerator Award (ACE)	American Diabe	tes Association, Inc.	23-Jul-2025	1,625,000 USD		
	Contact Name							
	Contact Telephone	800-342-2383						
	Contact Email	pathway@diabetes.org						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	23-Jul-2025						
	Synopsis	The Pathway to Stop Diabetes Accelerator Award is designed to support exceptional, independent early-career researchers who have distinguished themselves as promising investigators and are in the beginning stages of establishing successful, sustainable diabetes research programs. Awards will provide five years of research support up to \$325,000/year (including 30% indirect costs) for a total of \$1,625,000.						
	Applicant Types	3						
	Funding Limit	325,000.00 per year						



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
	Limited Submission	Yes						
048481	Pathway to Stop Diabetes - Init	iator Award (INI)	American Diabet	es Association, Inc.	23-Jul-2025	1,625,000 USD		
	Contact Name							
	Contact Telephone	800-342-2383						
	Contact Email	grantquestions@diabetes.org						
	Sponsor Website Link to sponsor website							
	Program URL	Link to program URL						
Deadline Dates (ALL) Pathway to Stop Diabetes® has a simple, yet revolutionary goal: to find scientists at the peak of their creativity provide them with the flexibility and resources they need on the road to breakthrough discoveries. The three focus-awarding research grants, providing access to scientific and career mentoring from leading diabetes researchers, and creating a diabetes think tank-are each key components of a unique formula to cultivate the generation of leaders, whose discoveries will stop diabetes and its burdens once and for all. Initiator Awards phased award is designed to support the transition of scientists from mentored training to independent rese faculty.								
								Applicant Types
	Funding Limit	1,625,000.00 see detail						
	Limited Submission	No						
076393	Rawls-Palmer Progress in Medi	cine Award	American Society Pharmacology ar		24-Jul-2025	5 1,000 USD		



SPIN ID Program Title		Sponsor Name	Sponsor Numbe	r	Deadline Date	Funding Amount		
	meetings@ascp							
Sponsor Website								
Deadline Dates (ALL)	Link to program 24-Jul-2025	IONL						
Synopsis	Award to furthe Rawls-Palmer P bridge the gap I focusing on rec	The American Society for Clinical Pharmacology and Therapeutics established the Rawls-Palmer Progress in Medicine Award to further his commitment to continuing medical education and its impact on patient care. The goal of the Rawls-Palmer Progress in Medicine Award is to incorporate the efforts of modern research in patient care and to help bridge the gap between the results of research and its application in patient care. The recipient will present a lecture ocusing on recent developments in clinical pharmacology. In addition, the recipient will receive a \$1,000 prize and a plaque. Travel expenses, hotel expenses, and meeting registration will be reimbursed by the Society.						
Applicant Types								
Funding Limit	1,000.00 see de	etail						
Limited Submission	No							
038894 Resident and Fellow Fast-Track	<u>c Grants</u>	Amer Hand	ican Society for Surgery of th	ie	26-May-202 [Optional]	5 5,000 USD		
Contact Name								
Contact Telephone	312-880-1900							
Contact Email	afsh@assh.org							
Sponsor Website	Link to sponsor	<u>website</u>						



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program	ı URL			
	Deadline Dates (ALL)	26-May-2025 [0	Optional], 07-Jul-2025 [LOI/Pre-Ap	p], 18-Aug-2025		
	Synopsis	innovative proje	pportunity is designed specifically ects related to hand surgery. The s AFSH basic science and clinical rese	cope of the project is smaller,	_	_
	Applicant Types					
	Funding Limit	5,000.00 maxim	num			
	Limited Submission	Yes				
088725 /	Allen Kerr Postgraduate Prize		Australasian	Plant Pathology Society	31-Jul-202	5 320 USD
	Contact Name	Prof. Andre Dre	enth			
	Contact Telephone					
	Contact Email	a.drenth@uq.ed	du.au			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	<u>ı URL</u>			
	Deadline Dates (ALL)	31-Jul-2025				
	Synopsis		Postgraduate Prize is awarded by the note of the Postgraduate of t			st piece of original
	Applicant Types					
	Funding Limit	500.00 see deta	ail			
	Limited Submission	No				
	Applicant Types Funding Limit	research releva 500.00 see deta	nt to Australasia by a postgraduate			st piece of original



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
013871	BLR Literary Prizes		Bellevue Literary	/ Review	01-Jul-2025	1,000 USD		
	Contact Name							
	Contact Telephone	212-263-3973						
	Contact Email	info@BLReview.	.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	01-Jul-2025						
	Synopsis	The BLR Prizes award outstanding writing related to themes of health, healing, illness, the mind, and the body. Winners are published in the spring issue of Bellevue Literary Review. For each genre, first prize is \$1000 and nonorable mention is \$300.						
	Applicant Types							
	Funding Limit	1,000.00 see de	tail					
	Limited Submission	No						
011230	BIRD Call for Proposals		Binational Indus Development (B	trial Research and IRD) Foundation	08-May-202 [LOI/Pre-Ap			
	Contact Name							
	Contact Telephone	972-3-6988300						
	Contact Email	See notes						
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	·							



SPIN ID Program Title		Sponsor Name	Sponsor Number	er D	eadline Date	Funding Amount			
Deadline Dates (ALL)	08-May-2025 [L	OI/Pre-App], 08-Jul-2025							
Synopsis	The Binational I and Israeli com	ndustrial Research and Developm panies.	ent (BIRD) Foundation	n provides su	upport for projects	s between U.S.			
Applicant Types	;								
Funding Limit	1,000,000.00 se	e detail							
Limited Submission	No								
130331 Translational Award		Brain Tumo	ur Charity		16-Jul-2025 [LOI/Pre-Ap	Not p] Specified			
Contact Name									
Contact Telephone									
Contact Emai	research@theb	raintumourcharity.org							
Sponsor Website	Link to sponsor	<u>website</u>							
Program URI	Link to program	URL							
Deadline Dates (ALL)	16-Jul-2025 [LO	I/Pre-App], 19-Nov-2025							
Synopsis	treatments to co of potential new studies with the	The sponsor funds projects that will bridge the gap between the research happening in the lab and getting new creatments to clinic. The Translational Award will provide funding of £300,000-£400,000 to support the development of potential new diagnostics, drugs, or devices. This funding is intended to cover key ex vivo/in vivo proof of concept studies with the aim of delivering focussed research within 12-18 months. Projects should have a clear pathway to patient benefit and can cover any modality for any primary brain tumour.							
Applicant Types	;								
Funding Limit	0.00 see detail								



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No				
042279	Breakthrough Prize in Life Scier	<u>nces</u>	Breakthrough Pri	ze	11-Jul-2025	3,000,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	office@breakthroughprize.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-Jul-2025				
	Synopsis	The Breakthrough Prize in Life Sciel extending human life. Each winner			understanding living	systems and
	Applicant Types					
	Funding Limit	3,000,000.00 maximum				
	Limited Submission	No				
	Request for Applications: Supp of Manufactured Islet Replacer	ortive Technologies for the Scaling ment Therapies	Breakthrough T1	D	28-May-202 [LOI/Pre-Ap	600 000 1180
	Contact Name	Nicholas Mamrak, Ph.D				
	Contact Telephone	800-533-2873				
	Contact Email	nmamrak@BT1D.org				
	Sponsor Website	Link to sponsor website				



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amo	ount		
	Program URL	Link to program URL							
	Deadline Dates (ALL)	28-May-2025 [LOI/Pre-App], 16-Jul-	2025						
	Synopsis	efficiency of scaling protocols for masupportive technologies tackling one generation beta cell replacement the	eakthrough T1D has issued a Request for Applications (RFA) offering a funding opportunity to improve the iciency of scaling protocols for manufactured islet cell therapies for type 1 diabetes (T1D) via development of opportive technologies tackling one or more of the barriers associated with implementation and expansion of next neration beta cell replacement therapies. This initiative will award grants to academic investigators and industry of the to \$600,000 over 2 years.						
	Applicant Types								
	Funding Limit	600,000.00 maximum							
	Limited Submission	No							
079141	Exceptional Project Grants		Breast Cancer Al	iance, Inc.	19-Jul-202	100,000) USD		
	Contact Name								
	Contact Telephone	203-861-0014							
	Contact Email	info@breastcanceralliance.org							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	19-Jul-2025							
	Synopsis	Breast Cancer Alliance invites clinical doctors and research scientists at any stage of their careers, including post docs whose current proposal is focused on breast cancer, to apply for an Exceptional Project Grant. This award recognizes creative, unique and innovative research related to breast cancer. The term of the Exceptional Project Grant is one year, beginning on March 1,2026. The grant provides salary support and project costs for a total of \$100,000,							



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		distributed over	r a one-year period. Indirect costs, whi	ch are included in the \$100	0,000 award, must k	e limited to 8% of
		total direct cost		·	,	
	Applicant Types					
	Funding Limit	100,000.00 max	rimum			
	Limited Submission	Yes				
059797 <u>Y</u>	oung Investigator Grant Progr	am_	Breast Cancer All	liance, Inc.	19-Jul-2025	125,000 USD
	Contact Name					
	Contact Telephone	203-861-0014				
	Contact Email	researchgrants@	@breastcanceralliance.org			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	19-Jul-2025				
	Synopsis	including post d	lliance invites clinical doctors and rese ocs, whose current proposal is focused int. This is a two-year grant for a total o	d on breast cancer, to appl		
	Applicant Types					
	Funding Limit	125,000.00 see	detail			
	Limited Submission	Yes				
130365 <u>C</u>	Climate Change and Human He	alth Seed Grants	Burroughs Wellco	ome Fund	24-Jul-2025	50,000 USD
	Contact Name	Victoria McGove	ern			



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	919-991-5112					
	Contact Email	vmcgovern@bw	rfund.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	24-Jul-2025					
	Synopsis	The Burroughs \ disconnected fie	Wellcome Fund aims to elds who might togethe	stimulate the ger change the co	growth of new connections ourse of climate change's i	s between thinkers mpact on human h	working in largely ealth.
	Applicant Types						
	Funding Limit	50,000.00 maxii	mum				
	Limited Submission	No					
074890	Team Grant: ERDERA Joint Tran	nsnational Call 20) <u>25</u> C	anadian Institut	tes of Health Research	16-Jul-202	5 324,000 USD
	Contact Name						
	Contact Telephone	613-954-1968					
	Contact Email	support-soutier	@cihr-irsc.gc.ca				
	Sponsor Website						
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	16-Jul-2025					
	Synopsis	this European R expanding and i	are Diseases Research mproving the diagnosis	Alliance (ERDERs and treatment	y 34 international funding (A) Joint Transnational Call c of rare diseases by creati researchers from across C	(JTC) 2025. CIHR-IONG the conditions n	G is committed to eeded to bring



SPIN ID	Program Title S		· Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types Funding Limit	studies on therapies using repurposed drugs or bioletc.). Proposals must conthrough cell, organoid and accelerate the success recorrelated to the efficient of pre-clinical studies in a studies for evidence of pinvestigational drug (i.e., support readiness for initial studies for initial studies.	etter health outcome for the ng small molecules, small nor logicals (e.g., antibodies or prover at least two of the following animal disease model stude of the pre-clinical stage; Ency of the therapy in a preclinan independent lab to increatharmacological activity in vite, small molecule(s) and/or big tiating clinical trial authorizations.	n-coding chemically synthes roteins such as enzymes, in ing areas: Development of dies, and/or use of in silico development of predictive a nical setting that could serv se validity of exploratory fi ro and in vivo, pharmaco-k plogic) and first toxicology	sized nucleic acid-banmune modulators on novel therapies in a por artificial intelliger and pharmacodynance as surrogate endpendings; Pre-clinical plantics and pharmacand safety data as we	preclinical setting nee models to nics biomarkers oints; Replication proof of concept co-dynamics of the
	Limited Submission	No				
062443 <u>I</u>	Fellowship: Health System Imp	act Fellowships	Canadian Institu	ites of Health Research	03-Jul-2025	Not Specified
	Contact Name					
	Contact Telephone	613-954-1968				
	Contact Email	support-soutien@cihr-ir	sc.gc.ca			
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	_				



SPIN ID	Program Title	Spons	or Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types	health services and po to critical challenges in public, private for-prof focused institutes), and	licy research, or related health system and rela it, not-for-profit, and In	s highly-qualified doctoral trained fields, a unique opportunity to a ted organizations outside of the digenous health organizations th al experience, new skills, and net	pply their research ar traditional scholarly s at are not universities	nd analytic talents etting (e.g.,
	Limited Submission	No				
113471	Texas New Technologies Comp Development Research	any Awards for Product	Cancer P Institute	revention and Research of Texas	10-Jul-2025	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	cprit@cprit.state.tx.us				
	Sponsor Website	Link to sponsor websit	<u>e</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Jul-2025				
	Synopsis	technologies for the defund new and emergin Development Research production of radionuc	etection, diagnosis, prog g technology projects th n RFAs. Proposals may in clides or their precurson	ne ongoing research and develop gnosis, monitoring, or treatment nat do not easily fit into any of th nclude, but are not limited to, bio s, manufacture of cell-based then h or clinical care, and biomanufa	of cancer. CPRIT creat the three other CPRIT Poinformatics, artificial trapies, processes to in	red this RFA to roduct intelligence, nprove the



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Applicant Types	appropriate justification, companie concept, product validation, design safety and efficacy.	•	• •	•	•
Funding Limit	0.00 not provided				
Limited Submission	Yes				
113470 Texas Diagnostic and Devices (Company Awards	Cancer Prevention		C-26.1- TDDC 10-Jul-202	Not Specified
Contact Name					
Contact Telephone					
Contact Emai	cprit@cprit.state.tx.us				
Sponsor Website	Link to sponsor website				
Program URI	Link to program URL				
Deadline Dates (ALL)	10-Jul-2025				
Synopsis	Funding available through this RFA treat, detect, diagnose, monitor, a cancer detection, diagnosis, prognameters for cancer prevention and distinguish high-risk early lesions company has developed a commer components/elements of the device human samples and whose import	nd assist in the trea osis, monitoring, tre I control, companio Senerally, at the tim rcial prototype of the ce. With respect to the	tment of cancer. Releval eatment and prediction on in diagnostic to a therapy e that an applicant appli ie device or a pictorial re diagnostics, the compan	nt areas include: Devor response or resist. Development of dia les to CPRIT pursuant presentation of the y has developed assa	vices and assays for ance to treatment agnostic tests to t to this RFA, the functional ays that work on



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Applicant Types	working toward submitting an Investand is typically within one year from stage of product development should only see detail	n filing an IDE (or la	ater stage work.) Potential	applicants that are	• •
	Limited Submission	No				
1134//	Texas Therapeutics Company A Research	wards for Product Development	Cancer Prevention Institute of Texas		10-Jul-2025	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	cprit@cprit.state.tx.us				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-Jul-2025				
	Synopsis	Funding available through this RFA and infrastructure with significant pidentified and characterized a lead models; completed pilot/dose rang manufacturing process, including redevelopment. The applicant is typic justification, companies may use CF concept (safety and efficacy) CMC/r	potential impact on compound; demor ing toxicology stud elease assays; and i ally within one yea PRIT funds to suppo	n patient care. Generally, an astrated efficacy in multiplices; determined the feasibidentified a prototype formar from filing an IND/IDE or the following: Studies t	t this stage, the con e translationally relo ility of a scalable, G nulation suitable for already in Phase 1 hat establish preclir	npany has evant animal MP compliant further With appropriate nical proof of



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
		to establish safety and a recom	mended dose for phase	e 2 Phase 2 studies to dete	ermine safety and ef	ficacy in initial
		targeted patient population				
	Applicant Types					
	Funding Limit	0.00 not provided				
	Limited Submission	No				
099221 /	Accelerating Impact for Hard-to	o-Treat Cancers Award	Children's Cance	r Research Fund	09-Jul-2025	250,000 USD
	Contact Name					
	Contact Telephone	952-893-9355				
	Contact Email	grants@childrenscancer.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Jul-2025				
	Synopsis	CCRF supports projects that encancers that remain hard-to-tre	able the prevention, ea	rly detection, treatment, a	and improve outcom	es of pediatric
	Applicant Types					
	Funding Limit	125,000.00 per year				
	Limited Submission	No				
019223 (Columbia Forensic Psychiatry F	ellowship	Columbia Univer	sity	16-Jul-2025	Not Specified
	Contact Name	Steven K. Hoge, MD; Director, (Columbia-Cornell Foren	sic Psychiatry Fellowship I	Program	



SPIN ID	Program Title	Sponsor	^r Name	Sponsor Number	Deadline Date F	unding Amount
	Contact Telephone	646-774-6342				
	Contact Email	skh2119@columbia.edu				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jul-2025				
	Synopsis		orensic Psychiatry Fellowship or experience, and supervision b		forensic psychiatry th	rough clinical
	Applicant Types					
	Funding Limit	0.00 not provided				
	Limited Submission	No				
000055	Research Fellowship Awards		Crohn's & Colitis	Foundation of America	06-May-2025 [LOI/Pre-App	710 000 080
	Contact Name	N'Dea Johnson				
	Contact Telephone	646-943-7501				
	Contact Email	training_awards@crohn	scolitisfoundation.org			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	18-Jul-2025				
	Synopsis	•	ards are intended to support i earch investigation in the field	•		•



SPIN ID	Program Title	Sponsor Name	e	Sponsor Number	Deadline Date Fu	Inding Amount				
	Applicant Types									
	Funding Limit	70,000.00 per year								
	Limited Submission	No								
001440	Career Development Awards		Crohn's & Colitis	Foundation of America	06-May-2025 [LOI/Pre-App]	180,000 USD				
	Contact Name	N'Dea Johnson								
	Contact Telephone	800-932-2423								
	Contact Email	training awards@crohnscolitis	sfoundation.org							
	Sponsor Website	<u>Link to sponsor website</u>								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	18-Jul-2025								
	Synopsis	Career Development Awards a research potential to prepare f bowel disease (IBD).			•					
	Applicant Types									
	Funding Limit	60,000.00 per year								
	Limited Submission	No								
000628	Senior Research Awards		Crohn's & Colitis	Foundation of America	06-May-2025 [LOI/Pre-App]	390,000 USD				
	Contact Name	Saleha Hossain								



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Telephone	800-932-2423					
	Contact Email	SRA@crohnscol	itisfoundation.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	18-Jul-2025					
	Synopsis	Senior Research data to become	Awards are intended to competitive for funds from	provide estat om other sou	olished researchers with furces such as the National I	inds to generate suf nstitutes of Health (I	ficient preliminary NIH).
	Applicant Types						
	Funding Limit	130,000.00 per	year				
	Limited Submission	No					
063869 <u>I</u>	Litwin IBD Pioneers Initiative		Cro	hn's & Colitis	Foundation of America	06-May-202 [LOI/Pre-Ap	130 000 1150
	Contact Name	Saleha Hossain					
	Contact Telephone						
	Contact Email	litwinprogram@	Ocrohnscolitisfoundation.	org			
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	18-Jul-2025					
		impact the trea	tment of IBD patients in t	he near futur	clinical and translational re. The program encourage, and cures for inflammate	es novel research int	o the diagnosis,



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount			
		innovative pilot research so that sci Pioneers supports researchers who improvements, including novel, out relevant focus. Additionally, the pro as countries outside the United Sta	are exploring all pos- c-of-the-box ideas, ogram is open to in	ossible opportunities for dand funds innovative and	liagnostic and therap pioneering ideas tha	eutic t have a clinically			
	Applicant Types								
	· ·	130,000.00 see detail							
	Limited Submission	Yes							
083322 -	rohn's & Colitis Foundation/N ward	ASPGHAN IBD Young Investigator	Crohn's & Colitis	Foundation of America	06-May-202 [LOI/Pre-Ap				
	Contact Name	N'Dea Johnson							
	Contact Telephone								
	Contact Email	training awards@crohnscolitisfoun	dation.org						
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	18-Jul-2025							
	Synopsis	Career Development Awards are mentored awards intended to facilitate the development of individuals with research potential to prepare for a career of independent basic research investigation in the area of inflammatory bowel disease (IBD).							
	Applicant Types								
	Funding Limit	0.00 see detail							



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount				
	Limited Submission	No								
002586	Grants Program		Cure Parkinsons	Trust	21-Jul-202	330,000 USD				
	Contact Name									
	Contact Telephone	0207 487 3892								
	Contact Email	Research@cureparkinsons.org.uk								
	Sponsor Website	Link to sponsor website								
	Program URL	Link to program URL	k to program URL							
	Deadline Dates (ALL)	21-Jul-2025 , 03-Nov-2025								
	Synopsis	This programme primarily funds pr Parkinson's. For preclinical researc prioritised. The sponsor only funds	h, projects that cou	ld lead to clinical trials in P						
	Applicant Types									
	Funding Limit	250,000.00 see detail								
	Limited Submission	No								
IIXhI/	CureSearch Young Investigator Cancer Drug Development	International Award in Pediatric	CureSearch for C	hildren's Cancer	16-Jul-202	5 225,000 USD				
	Contact Name									
	Contact Telephone	240-235-2215								
	Contact Email	researchgrants@curesearch.org								
	Sponsor Website	Link to sponsor website								



SPIN ID	Program Title		Sponsor Name	S	Sponsor Number	Deadline Date	Funding Amount	
	Program URL	Link to program	<u>URL</u>					
	Deadline Dates (ALL)	16-Jul-2025						
	CureSearch for Children's Cancer supports the recruitment of promising early-career scientists to a research career in pediatric oncology. The Young Investigator Program provides seed support for bright researchers, early in their careers, who are pursuing exciting and novel research in pediatric oncology. Young Investigator Award Funding provides up to \$75,000 per year for up to three years.							
	Applicant Types							
	Funding Limit 75,000.00 per year							
	Limited Submission	No						
089070	Myelodysplastic Syndromes (M	1DS) Research Fur	nd Dresner	(Vera and	Joseph) Foundation	07-Jul-2025	Not Specified	
	Contact Name							
	Contact Telephone	313-285-8618						
	Contact Email							
	Sponsor Website	Link to sponsor v	<u>website</u>					
	Program URL	Link to program	<u>URL</u>					
	Deadline Dates (ALL)	07-Jul-2025						
	Synopsis	as MDS/myelopi	understanding and treatment roliferative neoplasms (MPN) enia of undetermined signific	overlap sy	ndromes, secondary acu	ite myeloid leukemi	a following MDS,	



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
		the foundation established the M	IDS Research Fund (N	MDSRF). The fund will facilit	tate the advanceme	ent of innovative		
		basic science, translational or clir	•	,				
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						
006686	Cardiovascular Disease Fellows	hip Program	Emory University	у	15-Jul-2025	Not Specified		
	Contact Name	Lesia Waker, Program Coordinato	or					
	Contact Telephone	404-712-1504						
	Contact Email	waker@emory.edu						
	Sponsor Website	<u>Link to sponsor website</u>						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	15-Jul-2025						
	Synopsis	The goal of this ACGME-accredited training program is to train leaders in cardiovascular medicine through structured and systematic instruction in the science and art of cardiovascular disease. The training program emphasizes understanding of the entire spectrum of cardiovascular pathophysiology, from the molecular and cellular level to organ function and clinical presentation. Similarly, fellows receive excellent training in direct patient care, from bedside diagnosis to incorporation of state-of-the-art diagnostic and therapeutic management, with an emphasis on evidence-based and guideline-oriented diagnosis and therapy.						
	Applicant Types							
	Funding Limit	0.00 not provided						



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
Limited Submission	No						
010198 Practical Courses		European Molecular Biology Organisation (EMBO)		01-Jul-2025	Not Specified		
Contact Name							
Contact Telephone	+49 6221 8891 112						
Contact Email	courses_workshops@embo.org						
Sponsor Website Link to sponsor website Program URL Link to program URL							
Synopsis	EMBO Practical Courses provide to implement the techniques in their 25 participants. EMBO provides for registration and abstract submis	laboratories. The conding and assists or	ourses should last betweer	n five and ten days a	and are limited to		
Applicant Types							
Funding Limit	0.00 see detail						
Limited Submission	No						
028276 <u>Postdoctoral Fellowships</u>		European Molect Organisation (EN	.	11-Jul-2025	Not Specified		
Contact Name							
Contact Telephone	+ 49 6221 8891 112						
	1						



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount			
	Contact Email	fellowships@embo.org							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	11-Jul-2025							
	Synopsis	EMBO Postdoctoral Fellowships support excellent postdoctoral researchers throughout Europe and the world for a period of up to two years. International mobility is a key requirement. The fellowship includes a salary or stipend, a relocation allowance and support for fellows with children. Awardees can attend an EMBO Laboratory Leadership course and become part of the global network of EMBO Fellows.							
	Applicant Types								
	Funding Limit	0.00 see detail							
	Limited Submission	No							
057307 <u>F</u>	Research Grants	Fi	brolamellar Car	ncer Foundation	01-Jul-202	Not Specified			
	Contact Name	Payal Ray, PhD, FCF Research Program	Director						
	Contact Telephone								
	Contact Email	pray@fibrofoundation.org							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	01-Jul-2025 , 01-Nov-2025							
	Synopsis	The Fibrolamellar Cancer Foundation (I understanding and curative treatments	FCF) is accepting for fibrolamell	g proposals to support inn ar carcinoma (FLC). The re	ovative research le esearch must focus	ading to improved specifically on FLC.			



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Applicant Types	Studies should be intended to advatreatment of FLC. Of particular into with the ultimate goal of achieving and promising research projects to across institutions, together with exancers.	erest are application g a cure for FLC. The owards the listed goo	s showing a clear path to Foundation will accept gr als. The FCF believes that	wards a novel thera rant applications to collaboration engag	py or clinical trials support innovative jing the best talent
		0.00 see detail				
	Limited Submission					
	Lillited Subillission	140				
131047	Cardiovascular & Pulmonary Ph	hysical Therapy Research Grant	Foundation for Pl Research	hysical Therapy	31-Jul-202	5 40,000 USD
	Contact Name					
	Contact Telephone	1-800-875-1378				
	Contact Email	info@foundation4pt.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	31-Jul-2025				
	Synopsis	This grant supports diagnostic, pro that will decrease cardiovascular d	gnostic, rehabilitativ isease risks and imp	ve or therapeutic interver rove cardiovascular and p	ntion or practice in p oulmonary outcome	ohysical therapy s.
	Applicant Types					
	Funding Limit	40,000.00 see detail				



SPIN ID	Program Title	Sponsor	r Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No				
054952	Pediatric Physical Therapy Rese	earch Grant	Foundation for P Research	hysical Therapy	31-Jul-202	5 40,000 USD
	Contact Name					
	Contact Telephone	1-800-875-1378				
	Contact Email	info@foundation4pt.org	Z			
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	31-Jul-2025				
	Synopsis	One \$40,000 Pediatric Reconsistent with the curre	esearch Grant is to be awarde ent Academy of Pediatric Phys	d to an Emerging Investiga ical Therapy Research Age	tor that seeks to conda.	onduct research
	Applicant Types					
	Funding Limit	40,000.00 see detail				
	Limited Submission	No				
118344	118344 Orthopaedic Physical Therapy Research Grant			hysical Therapy	31-Jul-202	5 40,000 USD
	Contact Name					
	Contact Telephone	1-800-875-1378				
	Contact Email	info@foundation4pt.org	I			
	Sponsor Website	Link to sponsor website				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program	<u>ı URL</u>				
	Deadline Dates (ALL)	31-Jul-2025					
	Synopsis	outcomes of ph to applicants w	ysical therapy praction has been been definitionally with the definition meet the definition in the same are	ce for patients wit on of emerging inv	ch Grant will be awarded the musculoskeletal condition estigator. All the funded rood of either one or two ye	ons. This research g esearch must be ca	rant is open only
	Applicant Types						
	Funding Limit	40,000.00 maxi	mum				
	Limited Submission	No					
118346 <u>F</u>	118346 Paris Patla Manual Therapy Research Grant			Foundation for P Research	hysical Therapy	31-Jul-202	5 200,000 USD
	Contact Name						
	Contact Telephone	1-800-875-1378	3				
	Contact Email	info@foundatio	on4pt.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	31-Jul-2025					
The Foundation for Physical Therapy Research (FPTR) offers the Paris Patla Manual Therapy Research Grant to advance the therapeutic value of clinical manual therapy interventions and the evidence base for effective manual therapy practice for musculoskeletal conditions. All the funded research must be carried out in the United States (U.S.). The grant amount is \$200,000.							ffective manual



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
	Applicant Types						
	Funding Limit	200,000.00 maximum					
	Limited Submission	No					
093136	Physical Therapy Health Service	es Research Grant	Foundation for P Research	hysical Therapy	31-Jul-2025	40,000 USD	
	Contact Name						
	Contact Telephone						
	Contact Email	info@foundation4PT.org					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	31-Jul-2025					
		The Physical Therapy Health Services Research Grant builds on the successes of the ground-breaking Center on Healt Services Training and Research (CoHSTAR), which we launched in 2015 to address the need to train physical therapy researchers in health services research and implementation science. In particular, we have drawn from the experiences gained in the innovative and important physical therapy health services pilot studies program, which the center concluded in 2024.					
	Applicant Types						
	Funding Limit	40,000.00 maximum					
	Limited Submission	No					
062339	Foundation Research Grant		Foundation for P Research	hysical Therapy	31-Jul-2025	40,000 USD	



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Name						
	Contact Telephone	1-800-875-1378	3				
	Contact Email	info@foundatio	n4pt.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	31-Jul-2025					
	Synopsis	The Foundation for Physical Therapy Research's Foundation Research Grant supports research that evaluates the effectiveness of physical therapist interventions, within any discipline relevant to physical therapy, and addresses one or more priority area(s) of the APTA 2023 Research Agenda. The Foundation expects to make one (1) award of \$40,000 for a period of either one or two years.					
	Applicant Types						
	Funding Limit	40,000.00 maxi	mum				
	Limited Submission	No					
118343 <u>/</u>	Acute Care Physical Therapy Re	search Grant		Foundation for P Research	hysical Therapy	31-Jul-2025	80,000 USD
	Contact Name						
	Contact Telephone	1-800-875-1378	3				
	Contact Email	info@foundatio	n4pt.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	31-Jul-2025					



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Acute Care Physical Therapy Re physical therapy practice. All the ful \$80,000 for a period of either one of	nded research mus			
	Applicant Types					
	Funding Limit	80,000.00 maximum				
	Limited Submission	No				
120996 <u>F</u>	HESI THRIVE Grants		Health and Envir Institute (HESI)	onmental Sciences	28-Jul-202	5 50,000 USD
	Contact Name					
	Contact Telephone	+1-202-659-8404				
	Contact Email	Research@hesithrive.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	28-Jul-2025				
	Synopsis	The THRIVE grant program is design and collecting of preliminary data to major granting institutions.	•	•	•	• •
	Applicant Types					
	Funding Limit	50,000.00 maximum				
	Limited Submission	No				
081174	SWOG Early Exploration and De	evelopment (SEED) Fund	Hope Foundation	n for Cancer Research	01-Jul-202	5 50,000 USD



SPIN ID	Program Title	9	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
	Contact Name	Johanna Horn						
	Contact Telephone	734-998-7150						
	Contact Email	jo@thehopefoun	dation.org					
	Sponsor Website	Link to sponsor w	<u>vebsite</u>					
	Program URL	Link to program l	<u>JRL</u>					
	Deadline Dates (ALL)	01-Jul-2025						
	Synopsis	The Hope Foundation's SEED Fund for SWOG Early Exploration and Development aims to encourage preliminary research that will potentially translate to future clinical trials or trial-associated projects (translational medicine studies) within SWOG and the National Clinical Trials Network (NCTN). Individual projects may be funded for up to \$50,000 (direct costs) and may be spent over a 1- or 2-year award period.						
	Applicant Types							
	Funding Limit	50,000.00 maxim	ium					
	Limited Submission	No						
010629 <u>I</u>	IEEE Medal for Innovations in H	lealthcare Techno	llogv	Institute of Electi Engineers (IEEE)	rical and Electronics	15-Jun-202	5 Not Specified	
	Contact Name							
	Contact Telephone	732-562-3844						
	Contact Email	awards@ieee.org						
	Sponsor Website	Link to sponsor w	<u>vebsite</u>					
	Program URL	Link to program l	<u>JRL</u>					
	Deadline Dates (ALL)	15-Jun-2025 , 01-	-Jul-2025					



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
		The IEEE Medal for Innovations in H		•, .		•	
	Synopsis	and applications benefiting healthd criteria are considered: impact on t contributions; leadership in accomp publications or patents or other evi certificate, and cash honorarium.	he profession and/ olishing worthwhile	or society; succession of segoal(s); previous honors;	ignificant technical cother achievements	or other as evidenced by	
	Applicant Types						
	· ·	0.00 see detail					
	Limited Submission	No					
130607	IEEE Nick Holonyak, Jr. Medal f Technologies	or Semiconductor Optoelectronic	Institute of Electrical and Electronics Engineers (IEEE)		15-Jun-2025	Not Specified	
	Contact Name						
	Contact Telephone	732-562-3844					
	Contact Email	awards@ieee.org					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	15-Jun-2025 , 01-Jul-2025					
	Synopsis The IEEE Nick Holonyak, Jr. Medal is presented in recognition of outstanding contributions to semiconductor optoelectronic devices and systems including high-energy-efficiency semiconductor devices and electronics.						
	Applicant Types						
	Funding Limit	0.00 see detail					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title	Sponsor Na	ame	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No				
121039	Science is the Cure Grant		Kids Beating Car	ncer	01-Jul-2025 [LOI/Pre-Ap _l	Not o] Specified
	Contact Name	Sam Azar				
	Contact Telephone	407-894-2888				
	Contact Email	sam@kidsbeatingcancer.co	<u>m</u>			
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2025 [LOI/Pre-App],	15-Sep-2025			
	, .	The Science is the Cure Rescancers and solid tumors. Tawarding up to \$300,000 granslation studies that sup the ability to impact pediat	he Science is the Cure Res rants in a two-step format port therapeutic developr	earch Grant moves pediatr over a two or three-year p nent, biomarker research,	ric cancer knowledge eriod. This award is t	forward by o fund
	Applicant Types					
	Funding Limit	100,000.00 per year				
	Limited Submission	No				
108507 <u>J</u>	John and Maria Laffin Trust Gra	ant Program	Laffin (John and	Maria) Trust	31-Jul-2025	Not Specified
	Contact Name					
	Contact Telephone	1-888-235-4351				



Non Federal Funding Opportunities: July 2025

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Contact Email	grantadministra	ation @wellsfargo.com				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	31-Jul-2025					
	Synopsis	research, and h	uman services. Grants a	re made to edu	organizations supporting e ucational institutions at th , and humanitarian organi	e college and univer	
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
131138	New Investigator Pilot Study Av	<u>ward</u>	Le	wy Body Deme	entia Association (LBDA)	25-Jul-2025	50,000 USD
	Contact Name	Keith Fargo, Ph	D Director of Scientific Ir	nitiatives			
	Contact Telephone						
	Contact Email	kfargo@lbda.or	<u>g</u>				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	25-Jul-2025					
	The New Investigator Pilot Study Award is intended to support pilot translational or clinical studies for the purpose developing preliminary data to be used in future grant applications. The program is open both to early-stage investigators, and to more established researchers from other fields, who have not yet received an NIH R01 in Lew						



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
		body dementia (LBD) research. In	either case, the app	licant's career stage must	be no higher that as	sistant professor
		of equivalent.				
	Applicant Types					
	Funding Limit	50,000.00 maximum				
	Limited Submission	No				
077770	Emerging Leader Award		Mark Foundation	n for Cancer Research	28-Jul-2025	750,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	info@themarkfoundation.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	28-Jul-2025				
	Synopsis	The Mark Foundation Emerging Le leaders. These grants are awarded that are distinct from their curren	to outstanding earl			
	Applicant Types					
	Funding Limit	250,000.00 per year				
	Limited Submission	Yes				
079278	Canine Grants - Established Inv	restigators restigators	Morris Animal Fo	oundation	21-Jul-2025	5 100,000 USD
	Contact Name					



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
	Contact Telephone							
	Contact Email	grantapplicatio	ns@morrisanimalfoundation.or	g				
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	n URL					
	Deadline Dates (ALL)	21-Jul-2025						
	Synopsis	domestic dogs.	mal Foundation is now accepting Established Investigator grants record of research and publicat	are designed to provide fundi				
	Applicant Types							
	Funding Limit	100,000.00 see	detail					
	Limited Submission	No						
079279	Canine Grants Pilot Study Aw	<u>vards</u>	Morris Ar	imal Foundation	21-Jul-202	5 20,000 USD		
	Contact Name							
	Contact Telephone							
	Contact Email	grantapplicatio	ns@morrisanimalfoundation.or	g				
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	n URL					
	Deadline Dates (ALL)	21-Jul-2025						
	Synopsis	The mission of Morris Animal Foundation is to bridge science and resources to advance the health of animals. To achieve this mission, we fund hypothesis-driven, humane research projects with high scientific merit and the potential for significant impact. We are a nonprofit organization that is funded by public support from individuals,						



SPIN ID	Program Title	Spons	or Name	Sponsor Number	Deadline Date	Funding Amount	
	Applicant Types Funding Limit Limited Submission	research that results in stakeholders including 20,000.00 per year	d foundations, and earnings from impactful animal health achieved veterinarians, pet owners and control of the	ements and benefits both		_	
079281	Canine Grants First Award Gr	rant <u>s</u>	Morris Animal Fo	oundation	21-Jul-202	5 120,000 USD	
	Sponsor Website	grantapplications@mo Link to sponsor websit Link to program URL	orrisanimalfoundation.org <u>e</u>				
	Synopsis	The mission of Morris Animal Foundation is to bridge science and resources to advance the health of animals. To achieve this mission, we fund hypothesis-driven, humane research projects with high scientific merit and the potential for significant impact. We are a nonprofit organization that is funded by public support from individuals, corporations, clubs and foundations, and earnings from our endowed funds. Our donors are interested in funding research that results in impactful animal health achievements and benefits both scientific and non-scientific stakeholders including veterinarians, pet owners and communities.					
	Applicant Types Funding Limit	120,000.00 maximum					



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No				
079280	Canine Health Fellowship Tra	nining Grants	Morris Animal Fo	oundation	21-Jul-202	5 145,000 USD
	Contact Name					
	Contact Telephone	303-790-2345				
	Contact Email	grantapplications@morrisanima	lfoundation.org			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	21-Jul-2025				
		Morris Animal Foundation is now dogs. Fellowship Training grants providing salary support in a qua	are designed to assist	new investigators in laund		
	Applicant Types					
	Funding Limit	145,000.00 maximum				
	Limited Submission	No				
1 3114117	Army Research Laboratory (AR Fellowships	L) Distinguished Postdoctoral	National Academ	nies	10-Jul-2025	5 115,000 USD
	Contact Name					
	Contact Telephone	202-334-3478				
	Contact Email	arldpf@nas.edu				
	Sponsor Website	Link to sponsor website				



Program URL Deadline Dates (ALL) Deadline Dates (ALL) Deadline Dates (ALL) Army Research Laboratory (ARL) Distinguished Postdoctoral Fellowships provide early career researchers the opportunity to pursue independent research of their own choosing that supports the mission of ARL Candidates must display extraordinary ability in scientific research, show clear promise of becoming outstanding leaders, and are expected to have already successfully tackled a major scientific or engineering problem during their thesis work or to have provided a new approach or insight, evidenced by a recognized impact in their field. Applicants: Must demonstrate exceptional qualifications with respect to academic and scholarly achievement, as evidenced by research and publication. Are expected to have conducted research on a major scientific or engineering problem during their thesis work or have provided a new approach or insight evidenced by a recognized impact in their field. Applicant Types Funding Limit Limited Submission No 131144 NBDF-Sanofi Career Development Award National Bleeding Disorders Foundation Contact Name Halli Benasautti, PhD, Director of Research Grants Contact Telephone Sponsor Website Program URL Link to sponsor website Program URL Deadline Dates (ALL) 23-May-2025 [LOI/Pre-App], 03-Jul-2025	SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
Deadline Dates (ALL) Army Research Laboratory (ARL) Distinguished Postdoctoral Fellowships provide early career researchers the opportunity to pursue independent research of their own choosing that supports the mission of ARL. Candidates must display extraordinary ability in scientific research, show clear promise of becoming outstanding leaders, and are expected to have already successfully tackled a major scientific or engineering problem during their thesis work or to have provided a new approach or insight, evidenced by a recognized impact in their field. Applicants: Must demonstrate exceptional qualifications with respect to academic and scholarly achievement, as evidenced by research and publication. Are expected to have conducted research on a major scientific or engineering problem during their thesis work or have provided a new approach or insight evidenced by a recognized impact in their field. Applicant Types Funding Limit Limited Submission No 131144 NBDF-Sanofi Career Development Award National Bleeding Disorders Foundation Contact Name Contact Telephone Contact Telephone Contact Email Sponsor Website Program URL Limit to sponsor website Link to sponsor website Link to program URL								
Army Research Laboratory (ARL) Distinguished Postdoctoral Fellowships provide early career researchers the opportunity to pursue independent research of their own choosing that supports the mission of ARL. Candidates must display extraordinary ability in scientific research, show clear promise of becoming outstanding leaders, and are expected to have already successfully tackled a major scientific or engineering problem during their thesis work or to have provided a new approach or insight, evidenced by a recognized impact in their field. Applicants: Must demonstrate exceptional qualifications with respect to academic and scholarly achievement, as evidenced by research and publication. Are expected to have conducted research on a major scientific or engineering problem during their thesis work or have provided a new approach or insight evidenced by a recognized impact in their field. Applicant Types Funding Limit Limited Submission No Contact Name Halli Benasautti, PhD, Director of Research Grants Contact Telephone Contact Telephone Sponsor Website Link to sponsor website Link to program URL Link to program URL Link to program URL		Program URL	Link to program	URL				
opportunity to pursue independent research of their own choosing that supports the mission of ARL. Candidates must display extraordinary ability in scientific research, show clear promise of becoming outstanding leaders, and are expected to have already successfully tackled a major scientific or engineering problem during their thesis work or to have provided a new approach or insight, evidenced by a recognized impact in their field. Applicants: Must demonstrate exceptional qualifications with respect to academic and scholarly achievement, as evidenced by research and publication. Are expected to have conducted research on a major scientific or engineering problem during their thesis work or have provided a new approach or insight evidenced by a recognized impact in their field. Applicant Types Funding Limit Limited Submission 115,000.00 per year No Contact Name Halli Benasautti, PhD, Director of Research Grants Contact Telephone Contact Telephone Sponsor Website Program URL Link to sponsor website Link to program URL Link to		Deadline Dates (ALL)	10-Jul-2025					
Funding Limit Limited Submission No 131144 NBDF-Sanofi Career Development Award Contact Name Contact Telephone Contact Email Sponsor Website Program URL Link to program URL Link to program URL Link to program URL 115,000.00 per year National Bleeding Disorders Foundation 23-May-2025 [LOI/Pre-App] 210,000 USD 23-May-2025 [LOI/Pre-App] 210,000 USD 212-328-3746 Link to sponsor website Link to program URL		Synopsis	opportunity to p must display ext expected to hav have provided a demonstrate ex- research and pu	oursue independent research of their raced in a scientific research of their raced in a scientific research of the scientific research e already successfully tackled a majonew approach or insight, evidenced ceptional qualifications with respect blication. Are expected to have con	r own choosing that support ch, show clear promise of boor or scientific or engineering p by a recognized impact in t to academic and scholarly a ducted research on a major s	ts the mission of ARL ecoming outstanding or oblem during their heir field. Applicants achievement, as evid scientific or engineer	Candidates I leaders, and are Ithesis work or to	
Limited Submission No 131144 NBDF-Sanofi Career Development Award Contact Name Contact Telephone Contact Email Sponsor Website Program URL Limited Submission No National Bleeding Disorders Foundation 23-May-2025 [LOI/Pre-App] 210,000 USD 210		Applicant Types						
131144 NBDF-Sanofi Career Development Award Contact Name Contact Telephone Contact Email Sponsor Website Program URL National Bleeding Disorders Foundation 23-May-2025 [LOI/Pre-App] 210,000 USD 23-May-2025 [LOI/Pre-App] 210,000 USD 23-May-2025 [LOI/Pre-App] 210,000 USD 23-May-2025 [LOI/Pre-App] 210,000 USD 24-May-2025 [LOI/Pre-App] 210,000 USD 25-May-2025 [LOI/Pre-App] 25-May-2025 [LOI/Pre-App] 26-May-2025 [LOI/Pre-App] 27-May-2025 [LO		Funding Limit	115,000.00 per	year				
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Link to program URL		Limited Submission	No					
Contact Telephone Contact Email hbenasutti@bleeding.org Sponsor Website Program URL Link to program URL	131144	NBDF-Sanofi Career Developm	ent Award	National Bleed	ing Disorders Foundation	•	710 000 1180	
Contact Email hbenasutti@bleeding.org Sponsor Website Link to sponsor website Program URL Link to program URL		Contact Name	Halli Benasautti,	, PhD, Director of Research Grants				
Sponsor Website Link to sponsor website Program URL Link to program URL		Contact Telephone	212-328-3746					
Program URL Link to program URL		Contact Email	hbenasutti@bleeding.org					
		Sponsor Website	Link to sponsor	<u>website</u>				
Deadline Dates (ALL) 23-May-2025 [LOI/Pre-App], 03-Jul-2025		Program URL Link to program URL						
		Deadline Dates (ALL)	23-May-2025 [L	OI/Pre-App], 03-Jul-2025				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	,				
	Synopsis	NBDF is interested in funding innovative researcellular, animal or human/patient levels.	arch studies in bleeding disorders	s to be carried out at th	ne sub cellular,
	Applicant Types				
	Funding Limit	70,000.00 per year			
	Limited Submission	No			
078566 <u>F</u>	Research Grants Program	National	Rosacea Society	01-Jul-2025	25,000 USD
	Contact Name				
	Contact Telephone	847-382-8971			
	Contact Email	info@rosacea.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2025			
	Synopsis	The Society awards grants of up to \$25,000, or of rosacea is unknown, high priority is given to action, cell biology and potential genetic factors.	research in such areas as the pa	athogenesis, progression	on, mechanism of
	Applicant Types				
	Funding Limit	25,000.00 see detail			
	Limited Submission	No			
080002 \	Vulvodynia Research Award	National	Vulvodynia Association	20-May-202 [LOI/Pre-Ap	100 000 USD



SPIN ID Program Title	9	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
Contact Name	Phyllis Mate							
Contact Telephone	9							
Contact Ema	pmate@nva.org							
Sponsor Website	Link to sponsor w	<u>vebsite</u>						
Program UR	Link to program I	<u>URL</u>						
Deadline Dates (ALL) 20-May-2025 [LC	0I/Pre-App], 15-Jul-2025						
Synopsi	generalized vulvo maximum of \$10	The National Vulvodynia Association (NVA) is seeking research proposals on developing novel medical treatments for generalized vulvodynia or vestibulodynia. NVA research grants usually range from \$40,000 to \$80,000 with a maximum of \$100,000. Although NVA acknowledges the usefulness of CBT and mindfulness in coping with chronic pain, it is not funding psychosocial proposals at this time.						
Applicant Type	s							
Funding Limi	t 100,000.00 maxi	mum						
Limited Submission	No							
060162 Psychosocial Research Grants		Neilsen (Craig	H.) Foundation	10-Jul-2025	Not Specified			
Contact Name	Constanza Svidle	r						
Contact Telephone	818-925-1245							
Contact Ema	l constanza@chnf	oundation.org						
Sponsor Website	Link to sponsor w	<u>vebsite</u>						
Program UR	Link to program I	<u>URL</u>						
Deadline Dates (ALL) 10-Jul-2025							



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The Craig H. Neilsen Foundation's Ps and social wellbeing and research to and social welfare following spinal corregivers, clinicians, and communitiengagement. The portfolio seeks to design and execution.	develop and test interventions that in the injury (SCI). The goal is to build are can incorporate to address emotion	mprove an individual's me nd disseminate solutions th onal wellbeing and barriers	ental, behavioral, nat individuals, s to social
	Applicant Types Funding Limit Limited Submission	0.00 see detail			
103653		Nedical Research Award For the with Carbohydrate	North American Society for Pediatric Gastoenterology, Hepatology and Nutrition Foundation	01-Jul-2025	5 150,000 USD
	Sponsor Website	215-641-9800 naspghan@naspghan.org Link to sponsor website			
	Program URL Deadline Dates (ALL)				
	Synopsis Applicant Types	The NASPGHAN Foundation/QOL Me Maldigestion/Malabsorption in Child focused on disorders of carbohydrat	ren will provide \$75,000 annually for	two years (total \$150,000)) for studies



SPIN ID	Program Title	Sponsor Na	me	Sponsor Number	Deadline Date	Funding Amount	
	Funding Limit	75,000.00 per year					
	Limited Submission	No					
088368	088368 NASPGHAN Foundation/George Ferry Young Investigator Development Award			merican Society for Pediatric terology, Hepatology and n Foundation	01-Jul-2025	5 150,000 USD	
	Contact Name						
	Contact Telephone	none 215-641-9800					
	Contact Email naspghan@naspghan.org						
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	01-Jul-2025					
	Synopsis	clinical, quality improvemen	t, translational or	ge Ferry Young Investigator Devel basic science research project related of children. The award is \$75,000 in	ated to diseases of t	he gastrointestinal	
	Applicant Types						
	Funding Limit	75,000.00 per year					
	Limited Submission	No					
130819	130819 Celiac Disease Foundation/NASPGHAN Celiac Disease Pilot Grants			merican Society for Pediatric terology, Hepatology and n Foundation	01-Jul-2025	Not Specified	



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
	Contact Name								
	Contact Telephone	215-641-9800							
	Contact Email	naspghan@nas	naspghan@naspghan.org						
	Sponsor Website	<u>Link to sponsor website</u>							
	Program URL	Link to program	<u>URL</u>						
	Deadline Dates (ALL)	01-Jul-2025	1-Jul-2025						
	Synopsis	The Celiac Disease Foundation/NASPGHAN Celiac Disease Pilot Grants are designed to encourage and fund pilot projects in North America that address critical issues related to Celiac Disease and gluten-free diet management. The intent with this grant is to support Celiac Disease and gluten-free diet related innovative research or education proposals focused on new research areas that could improve the diagnosis and treatment of Celiac Disease; development of innovative tools or technologies to improve Celiac Disease management; research focused on understanding and improving adherence to the gluten-free diet among individuals with Celiac Disease, and research activities that have the potential to advance the nutrition care of patients and families of children with Celiac Disease.							
	Applicant Types								
	Funding Limit	0.00 see detail							
	Limited Submission	No							
001939 -	NASPGHAN Foundation/Taked nnovation Award	a Phamaceutical	Research	North American S Gastoenterology Nutrition Founda	,	01-Jul-2025	5 150,000 USD		
	Contact Name Contact Telephone								



Non Federal Funding Opportunities: July 2025

SPIN ID	Program Title	S	ponsor Name	Sponsor Number	Deadline Date	Funding Amount				
	Contact Email	grants@naspghar	n.org							
	Sponsor Website	Link to sponsor w	<u>ebsite</u>							
	Program URL	Link to program U	<u>JRL</u>							
	Deadline Dates (ALL)	01-Jul-2025	Jul-2025							
	Synopsis	This grant will provide \$75,000 annually for two years (total \$150,000) for innovative, high-impact research in sediatric gastroenterology, hepatology, and nutrition. The intent of this research award is to stimulate scientific inquiry in an area that is exceptionally innovative and has the potential to impact the field in a highly novel manner. The awardee must attend the NASPGHAN Annual Meeting in Chicago, Illinois, November 2025 to accept the award. The awardee agrees to present the results of the research project at the 2027 NASPGHAN Annual Meeting.								
	Applicant Types									
	Funding Limit	75,000.00 per yea	ar							
	Limited Submission	No								
099011	NASPGHAN Foundation Innova	tions in Clinical Ca	<u>re Grant</u> Gastoen	nerican Society for Pediatric erology, Hepatology and Foundation	: 01-Jul-202	5 Not Specified				
	Contact Name									
	Contact Telephone	215-641-9800								
	Contact Email	naspghan@naspg	han.org							
	Sponsor Website	Link to sponsor w	<u>ebsite</u>							
	Program URL	Link to program U	<u>JRL</u>							
	Deadline Dates (ALL)	01-Jul-2025								



SPIN ID	Program Title	Sponsor Nam	ne	Sponsor Nur	mber	Deadline Date	Funding Amount	
	Synopsis	The NASPGHAN Foundation Ir of innovative approaches to o	ptimize t	ne quality of care and health	care delivery	y to children with di	gestive diseases	
		by the clinically focused pedia \$2,000 to \$5,000 for a one-ye			on will award	up to two grants, e	ach ranging from	
	Applicant Types							
	Funding Limit	Funding Limit 0.00 see detail						
	Limited Submission	No						
130818	NASPGHAN Foundation/Sanofi Award for the Study of Pediatri Disorders		G	orth American Society for Pe astoenterology, Hepatology a utrition Foundation		01-Jul-202	5 150,000 USD	
	Contact Name							
	Contact Telephone	215-641-9800						
	Contact Email	naspghan@naspghan.org						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	01-Jul-2025						
	Synopsis	This grant is designed to support promising researchers in the early stages of their careers, fostering their potential to contribute significantly to independent research in pediatric eosinophilic gastrointestinal diseases. The award will support a meritorious clinical, quality improvement, translational or basic science research project related to pediatric Eosinophilic Esophagitis or other Eosinophilic Gastrointestinal Disorders. The award is \$75,000 in direct costs per year for up to two years of support.						
	Applicant Types							



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount				
		75,000.00 per year							
	Limited Submission	No							
099010	NASPGHAN Foundation/CPNP	Nutrition Research Grant	North American Society for Pediatric Gastoenterology, Hepatology and Nutrition Foundation	01-Jul-2025	Not Specified				
	Contact Name								
	Contact Telephone	tact Telephone 215-641-9800							
	Contact Email	naspghan@naspghan.org							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	01-Jul-2025							
		year award available to pediatric di	il for Pediatric Nutrition Professionals (CPNF letitians to support research activities that h les of children with nutritional disorders. Th for one year.	ave the potential to	advance the				
	Applicant Types								
	Funding Limit	0.00 see detail							
	Limited Submission	Limited Submission No							
UU 1986	NASPGHAN Foundation/APGNI Grant	N Susan Moyer Nursing Research	North American Society for Pediatric Gastoenterology, Hepatology and Nutrition Foundation	01-Jul-2025	5 5,000 USD				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount		
	Contact Name								
	Contact Telephone	215-641-9800							
	Contact Email	naspghan@nas	pghan.org						
	Sponsor Website	Link to sponsor	ink to sponsor website						
	Program URL	Link to program	<u>URL</u>						
	Deadline Dates (ALL)	01-Jul-2025							
	Synopsis	This one-year grant is available to pediatric gastroenterology, nutrition, and hepatology nurses to support research and/or quality improvement (QI) activities that have the potential to advance nursing care of patients and families of children with gastrointestinal, hepatobiliary, pancreatic or nutritional disorders. Monies are awarded in support of meritorious research and/or QI projects to study the nursing care of families and children with pediatric gastrointestinal, hepatobiliary, pancreatic or nutritional disorders.							
	Applicant Types								
	Funding Limit	5,000.00 maxim	num						
	Limited Submission	No							
099007 [099007 NASPGHAN Foundation Mid-Level Career Award		<u>d</u>	North American Gastoenterology Nutrition Founda	· •	01-Jul-202	5 100,000 USD		
	Contact Name								
	Contact Telephone	215-641-9800							
	Contact Email	grants@naspgh	an.org						
	Sponsor Website	Link to sponsor	<u>website</u>						



SPIN ID	Program Title	Sponsor N	lame	Sponsor Number	Deadline Date	Funding Amount			
	Program URL	Link to program URL							
	Deadline Dates (ALL)	01-Jul-2025							
	The North American Society for Pediatric Gastoenterology, Hepatology and Nutrition (NASPGHAN) Foundation offers a Mid-Level Career Award for members pursuing research in pediatric gastroenterology, hepatology, and nutrition. Synopsis Applications will be accepted for investigators to: support a new project within an established area of research; or, support investigation of a new or innovative research area which represents a departure from previously funded research.								
	Applicant Types								
	Funding Limit	50,000.00 per year							
	Limited Submission	No							
130444 (ORS/Bethel Fellowship Grant		Orthopaedic Res	earch Society	15-Jul-2025	Not Specified			
	Contact Name	Laurie Dearolf, PhD							
	Contact Telephone	847-823-5770							
	Contact Email	LBD25@pitt.edu							
	Sponsor Website	<u>Link to sponsor website</u>							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	15-Jul-2025							
	Synopsis	joined together to offer a	Society (ORS) and the Orlar fellowship to new-in-career kthrough treatments for mu	scientists. The Fellowship					



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
001067	Design and Development/Assis	tive Technology Grants	Paralyzed Vetera	ns of America	01-Jul-2025	200,000 USD
	Contact Name	Jennifer Massey				
	Contact Telephone	202-416-7639				
	Contact Email	jenniferm@pva.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2025				
	Synopsis	Paralyzed Veterans of America p rehabilitative and assistive techn improving the identification, seleto three years.	ology/devices for peo	pple with SCI/D to improve	function, which also	includes
	Applicant Types					
	Funding Limit	200,000.00 maximum				
	Limited Submission	No				
089497	Translational Research Grant		Pediatric Cancer	Research Foundation	01-Jul-2025	200,000 USD
	Contact Name	Rachael Kerchner, Grants Manag	ger			
	Contact Telephone	800-354-7273				



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
	Contact Email	rkerchner@pcrf-kids.org					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	01-Jul-2025					
	Synopsis	This grant is given to single or mulimplement new approaches to the the planning or initiation of a clini	erapy. These grants s	support "bench to bedside	" research, whose e		
	Applicant Types						
	Funding Limit	imit 100,000.00 per year					
	Limited Submission	Yes					
179948	Challenge AwardThe Pharmad Therapeutics	cology of Next Generation	Pharmaceutical F Manufacturers o Foundation	Research & f America (PhRMA)	01-Jul-202	5 5,000 USD	
	Contact Name						
	Contact Telephone						
	Contact Email	info@phrmafoundation.org					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	01-Jul-2025					
	Synopsis	The PhRMA Foundation and ASPE a Challenge Award competition th	T's Journal of Pharm at will award trainee	acology and Experimental es for outstanding papers a	Therapeutics (JPET addressing the phare) are partnering on macology of next	



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
	· ·	5,000.00 maximum	and JPET will publ	ish these accepted manus	cripts as part of a sp		
	Limited Submission				40.84 202	- 40 000 000	
1 1111X 4 4	<u> Lethality): Targeting Mechanisr</u>	ACceleration To Intercept CAncer ns of Lethal Prostate Cancer	Prostate Cancer I	Foundation	19-May-202 [LOI/Pre-Ap		
	Contact Name	Howard R. Soule, PhD, Executive Vic	e President				
	Contact Telephone	310-570-4700					
	Contact Email	applications@pcf.org					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	19-May-2025 [LOI/Pre-App], 09-Jul-	2025				
	Synopsis	The Prostate Cancer Foundation (PCF) is pleased to announce a Request for LOIs for PCF TACTICAL Awards from qualified teams of academic scientists that will specifically address the development of 21st Century therapies for lethal forms of prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world. PCF will fund 2-3 of these three-year awards for \$5 - \$10 Million U.S.D. per award.					
	Applicant Types						
	Funding Limit	10,000,000.00 maximum					



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date Fo	unding Amount			
	Limited Submission	No						
006942	Career Development Awards	Resea	arch to Prevent Blindness	15-Jun-2025 [LOI/Pre-App	350,000 USD			
	Contact Name	MariaClaudia Lora-Montano						
	Contact Telephone	646-892-9564						
	Contact Email	mlora@rpbusa.org						
	Sponsor Website	<u>Link to sponsor website</u>						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	15-Jun-2025 [LOI/Pre-App], 01-Jul-2025						
	Synopsis	The RPB Career Development Award helps ophthalmology faculty who have demonstrated payable for up to four (4) years upon approfund one (1) award that focuses on artificial focus will be funded by RPB.	rated their potential for independer oval of a 20-month substantive prog	nt research. The \$350,00 gress report. RPB is part	0 grant is nering to co-			
	Applicant Types							
	Funding Limit	350,000.00 maximum						
	Limited Submission	Yes						
070888 <u>I</u>	RPB Stein Innovation Awards	Resea	arch to Prevent Blindness	15-Jun-2025 [LOI/Pre-App	300,000 USD			
	Contact Name	MariaClaudia Lora-Montano						
	Contact Telephone	646-892-9566						



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	er	Deadline Date	Funding Amount
	Sponsor Website Program URL Deadline Dates (ALL)	Link to program 15-Jun-2025 [Lo The RPB Stein I understanding provide seed m demonstrates of researchers, bo function. For th research may a July deadline, s research may a SI Awards are in	<u>website</u>	es that compromise its gain vision science resolved in the visual system of Ophthalmology factors may be from any interpretable of proposed high-risk/lip	function. search which wards protestem and the culty who assitution of are activistitution of the culty of the culty who are activistitution of the culty was the culty was a search was a	These SI Awards are ch is innovative, cut vide funds to two graed diseases that comerce performing innovation in the performing innovation in the performing in innovation in the performing in innovation in the performing in the performance in the	intended to ting-edge, and oups of apromise its vative vision the U.S. For the vative vision the U.S. These
	Applicant Types						
	Funding Limit	300,000.00 ma	kimum				
	Limited Submission	No					
006943	Medical Student Fellowships		Research t	o Prevent Blindness		15-Jun-2025 [LOI/Pre-Ap	30 000 USD
	Contact Name Contact Telephone	MariaClaudia Lo 646-892-9564	ora-Montano				



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
		1						
	Contact Email	mlora@rpbusa	org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	ı URL					
	Deadline Dates (ALL)	15-Jun-2025 [L0	OI/Pre-App], 01-Jul-2025					
	Synopsis	medical school ophthalmology Ophthalmology specifically targ students of allo	The Medical Student Eye Research Fellowships allow gifted students to take a year off from allopathic or osteopathic medical school and devote time to the pursuit of a research project within an RPB-supported department of ophthalmology. Research to Prevent Blindness (RPB) is partnering with the American Osteopathic Colleges of Ophthalmology & Otolaryngology-Head and Neck Surgery Foundation (AOCOO-HNS) to offer one (1) award pecifically targeted to a student of osteopathic medicine. Additionally, RPB will offer various awards targeted to tudents of allopathic medicine. Both Fellowships will not have a specific discipline criteria or scientific focus and will be open to any topic within vision research. RPB encourages projects that incorporate artificial intelligence and/or lata science.					
	Applicant Types							
	Funding Limit	30,000.00 see d	letail					
	Limited Submission	Yes						
006934	Unrestricted Grants		Rese	earch to Preve	ent Blindness	01-Jul-202	5 575,000 USD	
	Contact Name	MariaClaudia L	ora-Montano					
	Contact Telephone	646-892-9564						
	Contact Email	mlora@rpbusa	org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	ı URL					



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	- "	la aaa-				
	Deadline Dates (ALL)					
	Synopsis	annual \$115,00 grants which so full-time, perma only be used fo (new purchase)	ed Grants provide maximum flexily of grants provide opportunities for ientists normally depend upon for anent chair at university-connectors the following: salaries (new or expending pilot research in vision scientical analysis, etc.); and travel research in vision sections.	r creative planning that go be r their principal support. Only ed medical schools are eligible xisting research faculty, not a ence; research support (include	eyond the scope of resort the scope of resort the scope of the scope o	stricted project thalmology with a icted Grants may t staff); equipment
	Applicant Types					
	Funding Limit	115,000.00 per	year			
	Limited Submission	No				
006935	Challenge Grants		Research to	Prevent Blindness	01-Jul-202	5 300,000 USD
	Contact Name	MariaClaudia Lo	ora-Montano			
	Contact Telephone	646-892-9564				
	Contact Email	mlora@rpbusa.	org			
	Sponsor Website	Link to sponsor	website			
	Program URL	Link to program	<u> URL</u>			
	Deadline Dates (ALL)	01-Jul-2025				
	Synopsis	department cha Challenge Gran	Grants encourage growth for new airs at non-grantee ophthalmolog t is designed to enhance a depart orative studies of the visual syste	y departments at university-c ment's environment and capa	connected medical sch ability to conduct vision	nools. The on research, to



SPIN ID	Program Title	Spons	sor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types	equipment (new purch consumables, data gat	the following: salaries (new or exnase); small pilot research in visithering, statistical analysis, etc.);	on science; research supp	ort (including lab su	• •
	Funding Limit	300,000.00 maximum				
	Limited Submission	No				
070892	RPB International Research Col	laborators Award	Research to Prev	rent Blindness	16-Jun-202 [LOI/Pre-A	75 NNN LISD
	Contact Name	MariaClaudia Lora-Mo	ntano			
	Contact Telephone	646-892-9564				
	Contact Email	mlora@rpbusa.org				
	Sponsor Website	Link to sponsor websit	<u>te</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2025 [LOI/Pre-	App], 01-Jul-2025			
	Synopsis	collaborating research collaborations have the affecting large populate each researcher and to accomplished by each knowledge and skills; a	Research Collaborators Award pages in the U.S. and outside the Use potential to accelerate the detions worldwide for years to conto the culminating project. The softhe collaborating researchers and (2) strengthening collaboration of each researcher, who	J.S. gain new knowledge a velopment of treatments the collaboration shout the collaboration shout the spell out so toward the fulfillment of the cions across international between the state of the constitution of the constitut	nd skills. These interfor blinding disorderald provide a synergopecific and cogent two broad goals: (poundaries. Succes	ernational ers, positively gistic benefit to objectives to be 1) gaining new sful candidates will



SPIN ID	Program Title	Spoi	nsor Name	Sponsor Number	Deadline Date	Funding Amount
		than the sum of its p	arts. An award of up to	\$75,000 is available. Matching fu	ınds are not required	, however, a match
		is encouraged by the	e department and/or the	ne institution outside the U.S.		
	Applicant Types					
	Funding Limit	75,000.00 maximum				
	Limited Submission	Yes				
000622	Scientist Development Award		Rheui	matology Research Foundation	01-Jul-202 [LOI/Pre-A	225 000 HSD
	Contact Name					
	Contact Telephone	404-365-1373				
	Contact Email	Foundation@rheuma	atology.org			
	Sponsor Website	Link to sponsor webs	<u>site</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2025 [LOI/Pre	-App], 01-Aug-2025			
	Synopsis	research experience structured research to mentored career devicearly years of research investigators. The government and research awards. Through this	who plan to embark o training program for rh velopment award prov ch training in an enviro val of funding at this lev ch training that will allo	e early stages of their career, typical neareers in rheumatic diseases. The eumatologists or health profession ides support for salary as well as resonment where trainees may interacted is to provide an opportunity for ow them to be competitive for the in provides a means for ensuring manager of the end of	ne purpose of this aw nals in the field of rhe esearch and/or educa ct with established rh young scientists to e next level of career d	ard is to provide a cumatology. This tion costs for the eumatology mbark on focused evelopment



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	unding Amount
	Applicant Types				
	Funding Limit	'5,000.00 per year			
	Limited Submission	No			
002115 <u>I</u>	nvestigator Award	Rheum	atology Research Foundation	01-Jul-2025 [LOI/Pre-App	375,000 USD
	Contact Name				
	Contact Telephone	04-365-1373			
	Contact Email	oundation@rheumatology.org			
	Sponsor Website	ink to sponsor website			
	Program URL	ink to program URL			
	Deadline Dates (ALL)	1-Jul-2025 [LOI/Pre-App], 01-Aug-2025			
	Synopsis	This award is intended to support early-stage leveloping a project that will be competitive postdoctoral fellowship. The purpose is to pu engaged in research relevant to the rheumate ellowship training and establishment as an i	for NIH and/or equivalent funding ovide support for basic science, tracic diseases for the period between	g. It is not intended to be anslational, and clinical	e a second investigators
	Applicant Types				
	Funding Limit	75,000.00 maximum			
	Limited Submission	No			
046418	Science & SciLifeLab Prize for Y	ung Scientists Science	!	15-Jul-2025	30,000 USD



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount	
	Contact Name							
	Contact Telephone	202-326-6417						
	·	SciLifeLabPrize@	@aaas.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					
	Deadline Dates (ALL)	15-Jul-2025						
	Synopsis	The Science & SciLifeLab Prize for Young Scientists is awarded annually to one young scientist for outstanding life science research for which they were awarded a doctoral degree in the previous two years. The topic of the entrant's thesis research must be in one of the following categories: Cell and Molecular Biology; Genomics, Proteomics, and Systems Biology approaches; Ecology and Environment; Molecular Medicine. The grand prize winner receives \$30,000 USD and each of the other three category winners receives \$10,000 USD.						
	Applicant Types							
	Funding Limit	30,000.00 maxii	mum					
	Limited Submission	Yes						
125145 /	Autism & Neuroscience Confer	ences and Cours	es Awards	Simons Foundati	on	22-May-202 [LOI/Pre-Ap		
	Contact Name							
	Contact Telephone	646-654-0066						
	Contact Email	neurogrants@s	monsfoundation.org	I				
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	URL					



SPIN ID	Program Title	Sponsor Nar	ne	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	22-May-2025 [LOI/Pre-App],	24-Jul-2025			
	Synopsis	The Autism & Neuroscience conferences. This year, cours programs will be prioritized: basic science of autism and r Aging Brain (SCPAB), with a f (SCGB), with a focus on the f	es and conferences that Simons Foundation Autis elated neurodevelopmer ocus on healthy cognitive	align with the scientific mism Research Initiative (SFA ntal disorders, the Simons of e aging, and the Simons Co	ssions of any of the RI), with a mission to Collaboration on Pla	following o advance the sticity and the
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
032017	Research Grants Program		Skin Cancer Fou	ndation	12-Jul-2025	50,000 USD
	Contact Name					
	Contact Telephone	212-725-5176				
	Contact Email	research@skincancer.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Jul-2025				
	Synopsis	The Foundation awards reservered prevention, detection and tro		er investigators to support	pilot research proje	cts related to
	Applicant Types					
	Funding Limit	50,000.00 maximum				



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	No				
066849	Mentored Clinical Scientist Res (K08)	earch Career Development Award	Society for Vascu	lar Surgery	12-Jun-202	Not Specified
	Contact Name					
	Contact Telephone	800-258-7188				
	Contact Email	svsfoundation@vascularsociety.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Jun-2025 , 12-Jul-2025 , 12-Oct-2	2025 , 12-Nov-2025			
	Synopsis	The Mentored Clinical Scientist Reso for careers that have a significant in support and protected time for an i biomedical, behavioral, or clinical re	npact on the health ntensive, supervise	n-related research needs o d research career develop	f the Nation. This pr	ogram provides
	Applicant Types					
	Funding Limit	50,000.00 per year				
	Limited Submission	No				
123676	Pilot Award Program for Myelo	dysplastic Syndrome Research	Taub (Henry and	Marilyn) Foundation	01-Jul-2025	100,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	mdsgrants@taubfoundation.org				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
		1							
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	<u>ı URL</u>						
	Deadline Dates (ALL)	01-Jul-2025							
	Synopsis	ideas that can f for proof-of-cor projects will ger mechanisms. Th	Henry and Marilyn Taub Foundation (HMTF) 2025 Pilot award will provide seed money to pursue transformative that can forge new scientific directions and strategies in MDS research. The one-year award provides \$100,000 roof-of-concept studies addressing critical roadblocks to understanding MDS and its treatment. Successful cts will generate preliminary data needed to support their extension and expansion through other funding nanisms. The research must be non-incremental and may include high-risk/high-reward or collaborative efforts to porate new technologies and approaches from other fields.						
	Applicant Types								
	Funding Limit	100,000.00 max	ximum						
	Limited Submission	No							
001193	E.W. Al Thrasher Awards		Thrasher Res	earch Fund	15-Jul-2025 [LOI/Pre-Ap	Not p] Specified			
	Contact Name	Allison Martine	z, Executive Assistant						
	Contact Telephone	801-240-4753							
	Contact Email	Allison@Thrash	nerResearch.org						
	Sponsor Website	Link to sponsor	website						
	Program URL	Link to program	ı URL						
	Deadline Dates (ALL)	15-Jul-2025 [LO	l/Pre-App], 30-Oct-2025						
		•							



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount		
		E.W. "Al" Thrasher Awards focus on projects that	are changing pediatric clinical ca	are. Each award is	a novel approach		
		to problems plaguing pediatrics. The award is open to applications focusing on any disease or topic within the umbrella of pediatrics, both in and outside the United States.					
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
003397	Wellington Doctoral Scholar	<u>rships</u>	Victoria University of Wellin	gton 01-Jul-202	25 52,215 USD		
	Contact Name						
	Contact Telephone	64 4 472 1000					
	Contact Email	pg-research@vuw.ac.nz					
	Sponsor Website	<u>Link to sponsor website</u>					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	01-Jul-2025 , 01-Nov-2025					
	Synopsis	These scholarships are intended to encourage an Wellington. To encourage postgraduate research to begin their doctoral studies. These scholarship international students in any discipline.	Victoria University of Wellington	n offers scholarsh	ips to those about		
	Applicant Types						
	Funding Limit	29,500.00 per year					
	Limited Submission	No					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
130430	Mental Health Award: Adva Drug Discovery	ncing Target Validation for Novel Mental Health	Wellcome Trust	31-Jul-2025	924,000 USD
	Contact Name				
	Contact Telephone	0 20 7611 5757			
	Contact Email				
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Jul-2025			
	Synopsis	This call will provide funding for validation activition biological rationale related to early intervention in generate data supporting the target's therapeutic pharmacological treatments.	n anxiety, depression and/or ps	ychosis. Funded pro	posals will
	Applicant Types				
	Funding Limit	700,000.00 maximum			
	Limited Submission	No			
130768	Discovery and Innovation A	<u>ward</u>	Western New York BloodCa	are 01-Jul-2025	450,000 USD
	Contact Name	Marci Wiseman, Grant and Award Administrator			
	Contact Telephone	716-896-2470			
	Contact Email	mwiseman@wnybloodcare.org			
	Sponsor Website	<u>Link to sponsor website</u>			



The Development Office offers assistance with many not for profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team at DevCorpFound@mountsinai.org / 212-659-8500 for assistance or questions.

Sponsor Number

Deadline Date

Funding Amount

Sponsor Name

	ı			
Program URL	Link to program U	<u>JRL</u>		
Deadline Dates (ALL)	01-Jul-2025			
Synopsis	New York and the clinical research p	s been established to promote, nurture e region. The WNYBC Discovery and In projects that will improve health outco or hemostatic or thrombotic disorders	novation Award will suppo omes, health equity, and/o	
Applicant Types				
Funding Limit	150,000.00 per ye	ear		
Limited Submission	No			



Program Title

SPIN ID